Discovery of new therapeutic targets in Neuroblastoma by means of proteomic approach and functional studies by Cimmino, Flora
 1
 
EUROPEAN SCHOOL OF MOLECULAR MEDICINE 
SEDE DI NAPOLI 
UNIVERSITA’ DEGLI STUDI DI NAPOLI “FEDERICO II” 
Ph.D. in Molecular Medicine – Ciclo III/XXI 
Curriculum scelto (tra Molecular Oncology e Human Genetics) 
 
 
 “Titolo della tesi”  
 
Discovery of new therapeutic targets in Neuroblastoma by means 
of proteomic approach and functional studies 
 
Tutor: 
Prof. Achille Iolascon 
Internal Supervisor: 
Prof. Brunella Franco 
External Supervisor: 
Prof. Angelika Eggert 
Coordinator: 
Prof. Francesco Salvatore 
         Ph.D. student: Flora Cimmino 
 
Academic Year: 2008-2009 
 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3
Table of Content 
 
Abstract………………………………… …….........pag.11 
 
 
Introduction………………………………………....pag.13 
 
1.Neuroblastoma 
1.1 Neuroblastoma……………………………………............pag. 13 
1.2Pathology: Cell of origin and stem cell hypotesis……......pag. 14 
 
 
2.Neuroblastoma Heterogeneity 
2.1 Clinical presentation and staging………………………...pag 16 
2.2 Genetic Heterogeneity…………………………………….pag 18 
2.3 Tumor Biology………………………………………...…...pag 23 
 
 
3. Neuroblastoma Therapy…………………………..………..pag 26 
3.1 Retinoic Acid…………………………………………..…..pag 27 
 
 
4. Neurothrophin Receptors………………………….….........pag 31 
4.1 Biological role of Trk receptors in  neuroblastoma……..pag 35                                       
 
 
5. Galectin-1……………………………………………….…...pag 36 
 
 
 4
6. Discovery of new therapeutic targets in     Neuroblastoma by 
means of proteomic approach an functional studies……..…pag 40 
6.1 First Aim……………………………………………...……pag 41 
6.2 Second Aim………………………………………………...pag 43 
 
 
Matherial and Methods…………………………….pag 44 
 
 1. Cell Culture…………………………………………..…….pag 44 
 1.1 Cell Culture and characteristics of stable transfectants 
 1.2 Neuronal Differentiation…………………………………pag 45 
 
 
2.Two Dimensional-differential in gel electrophoresis (2D-DIGE) 
 
2. 1. Cytosolic Protein Fraction Preparation………….……..pag 45 
2.2 Nuclear Protein Fraction Preparation...............................pag 46 
2.3 Cy-Dye Labeling of Cytosolic and Nuclear Fraction Extracts 
 
2.4 2-D Gel Electrophoresis, Imaging, and DIGE Analysis...pag 47 
 
 
3 Protein Identification by MS.  
3.1. MALDI MS Analysis………………………………….….pag 49 
3.2. LC-MS/MS Analysis……………………………….……..pag 50 
3.3 Protein Identification by Bionformatic Tools ……..…… pag 51 
 
 
4. Data Mining……………………………………………..…..pag 52 
 
 
5. Western Blotting. …………………………………..............pag 53  
 5
 
 
6. siRNA transfection …………………………………...…….pag 54 
 
 
7. Cell proliferation analysis……………………..…………...pag 54 
8. Reverse transcriptase PCR and microarray analyses….pag 55 
 
 
9. Cell invasion assay………………………………………...pag 55 
 
 
10. Cell migration assay……………………………………..pag 56 
 
 
11. Immunohistochemistry………………………………….pag 57 
 
 
Results……………………………………………….pag 58 
 
 
1. DIGE Analysis of Differentially Expressed Proteins following 
ATRA Treatment in the LAN-5 NB Cell Line………………pag 58 
1.1 Subcellular fractionation …………………………………pag 59 
1.2 Two-Dimensional Differential In-Gel Electrophoresis (2D-
DIGE) analyse……………………………...………………….pag 59 
1.3 Hierarchical Clustering Analysis…...…………………….pag 61 
 
 
2. Mass Spectrometry…………………...…………………….pag 63 
 
 
3. Gene Ontology ………………………..…………………….pag 66 
 
 
 6
4. Gene Mapping………………………….…………………  .pag 68 
 
 
5. Validation and Analysis in Different Human NB Cell Lines 
……………………………………………..……………………pag 69 
 
 
6. VBP1 survival correlation in primary NB……………..….pag 73  
 
 
7. Gal-1 mRNA expression correlates with neurotrophin receptor 
expression in primary NB…………………………………….pag 74 
 
 
8. Gal-1 protein is highly expressed in primary NB………...pag 76 
 
 
9 Gal-1 contributes to BDNF-mediated invasion of SY5Y-TrkB 
cells……………………………………………………………..pag 77 
9.1 Gal-1 silencing by siRNA………………………….……....pag 79 
 
10.  
Downregulation of Gal-1 abrogates migration of SY5Y-TrkB 
cells……………………………………………………….…….pag 80 
 
 
11. Gal-1 is strictly dependent on TrkB pathway…………...pag 81 
 
 
Discussion…………………………………………...pag 83 
 
1.First Aim: 
Comparative proteomic expression profile in All-trans Retinoic 
Acid differentiated NB cell line……………………...………..pag 84 
 
 
2. Second Aim:  
Galectin-1 is a major effector of aggressiveness in TrkB-
expressing NB………………………………………………….pag 93 
 
 
 7
List of abbreviations 
 
NB: neuroblastoma 
RA: retinoic acid 
ATRA: all-trans-retinoic acid 
2D-DIGE: two dimensional-differencial in gel 
electrophoresis 
MS: mass spectrometry 
VBP-1: Von Hipple-Lindau binding protein 1/prefoldin 
3 
TrkA: tyrosin kinase receptor A 
TrkB: tyrosin kinase receptor B 
BDNF: brain derived neurotrophin factor 
NGF: nerve growth factor 
Gal-1: galectin-1 
 
 
 
 
 
 
 8
Figure index 
 
Figure 1: Neural crest cells formation during embryonic development. 
…………………………………………………………………..pag 14 
Figure 2: International Neuroblastoma Staging System (INSS) pag 18 
Figure 3: Mostly frequent genetic abnormalities in Neuroblastoma 
………………………………………………………………….pag 22 
Figure 4: Retinoic Acid: mechanism of action  ……………….pag 30 
Figure 5:Trk receptors and ligands…………………………….pag 33 
Figure 6: Transducton signal of Trk receptors…………………pag 35 
Figure 7: Galectin family………………………………………pag 37 
Figure 8:Galectin-1 and cancer progression…………………...pag 39 
Figure 9: Checking the cytosol and nucleus protein fractions…pag 59 
Figure 10: 2D-DIGE gel images……………………………….pag 61 
Figure 11: Hierarchical clustering analysis…………………….pag 62 
Figure 12: The differentially expressed protein spots upon ATRA 
treatment………………………………………………………..pag 64 
Figure 13: Gene ontology……………………………………...pag 67 
Figure 14: Western blot analysis of selected proteins in LAN-5 cells 
…………………………………………………………………..pag 70 
Figure 15: Western blot analysis of selected proteins was performed 
in LAN-5, SH-SY5Y and SK-N-BE cells………………………pag 71 
 9
Figure 16: Prefoldin 3 and DDX1 ATRA differentially expression 
…………………………………………………………………..pag 72 
Figure 17: VBP1 expression survival in NB…………………...pag 73 
Figure 18: Correlation of Gal-1 and Trk expression in primary NB 
…………………………………………………………………..pag 74 
Figure 19: Gal-1 expression in SY5Y cells…………………….pag 75 
Figure 20: rGal-1 mediated effects……………………………..pag 76 
Figure 21: Immunohistochemical staining of Gal-1 in primary NB 
…………………………………………………………………..pag 77 
Figure 22: Invasion mediated by TrkB stimulation ……………pag 77 
Figure 23: Gal-1 contributes to BDNF-mediated invasion…….pag 79 
Figure 24: . Extracellular Gal-1 effect on TrkB mediated.invasion. 
…………………………………………………………………..pag 79 
Figure 25: . Gal-1 expression silencing………………………...pag 80 
Figure 26: Gal-1 effect on TrkB mediated.migration…………..pag 81 
Figure 27: Gal-1 is strictly dependent on TrkB pathway activation 
…………………………………………………………………..pag 82 
 
 
 
 
 
 10
Table Index 
 
Table 1: Experimental Design of 2D-DIGE……………………pag 60 
 
Table 2: Proteins identified in the cytosolic fraction…………...pag 65 
Table 3: Protein identified in the nuclear fraction  …………….pag 65 
Table 4: Mapped Chromosomal regions of genes coding for the 
identified proteins……………………………………………….pag 69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11
Abstract 
 
Neuroblatoma (NB) is an embryonal tumor of the sympathetic 
nervous system which arises from the neural crest cells. This disease 
rappresents the most common extracranial tumor in infants, 
accounting for 8% to 10% of all childhood cancer and for 
approximately 15% of cancer deaths in children. 
NB is a heterogeneous tumor for which biology dictates clinical 
behaviour.  
It comprises cases with divergent outcome ranging from spontaneous 
differentiation to metastatic forms with poor prognosis. The deep 
knowledge of NB biology is imperative toward the development of 
novel therapy.  
The most favourable subset of  NB (stage 4S) can spontaneously 
differentiate in neurons or regress to a benign tumour phenotype. 
Retinoic Acid (RA) is a known neural differentiation-inducing agent 
actually used in NB therapy. In order to get new insights in the 
molecular mechanism driving neuronal differentiation in vitro, two-
Dimensional Differential In-Gel Electrophoresis (2D-DIGE) analyse 
was performed on the cytosolic and nuclear protein expression 
patterns of NB cells following RA treatment. The combination of a 
proteomic approach and sub-cellular fractionation of the proteome 
provides the identification of 33 differentially expressed proteins 
during RA treatment in NB. The identified proteins have important 
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roles in a variety of pathways which may have role on NB 
development and in NB RA-induced differentiation. The results also 
strength the use of proteomics to discover new putative protein targets 
in cancer. 
Expression of Trk receptors is an important prognostic factor in NB. 
TrkB and its ligand BDNF (brain derived neurotrophin factor) are 
preferentially expressed in NB with poor prognosis, conferring 
invasive and metastatic potential to the tumor cells as well as 
enhancing therapy resistance. TrkA in contrast is high expressed in 
tumor with good outcome. Galectin-1 (Gal-1), a very promising 
cancer target, is involved in modulating cell proliferation, cell death 
and cell migration and was found to be up-regulated in patients with 
aggressive, relapsing NB. Gal-1 is a down-stream mediator of TrkB 
signalling, since its espression is increased in human SY5Y NB cells 
upon activation of ectopically expressed TrkB (SY5Y-TrkB), but not 
TrkA (SY5Y-TrkA). Functional studies here presented underlined the 
Gal-1 role to mediate invasion and migration in TrkB over-expressing 
NB cells, thus being activated by BDNF. This establishes Gal-1 as a 
potential therapeutic marker in high-risk TrkB-expressing NB. 
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Introduction 
 
1.Neuroblastoma 
 
1.1 Neuroblastoma 
Neuroblastoma (NB) is an embryonal tumor of neuroectodermal cells 
derived from the neural crest and destined for the adrenal medulla and 
sympathetic nervous system (Brodeur  2003; Maris et al., 1999). 
This disease is the most common extracranial solid tumor in the 
pediatric population accounting for 8% to 10% of all childhood cancer 
and for approximately 15% of cancer deaths in children. The 
incidence per year is 10,5 per million children less than 15 years of 
age. 30% of all cases occur in the first year of life and nearly half of 
the newly diagnosed patients are between the age 1 and 4 years 
(Stiller et al., 1992; Park et al., 2008). 
The etiology  of NB remains obscure. Despite the fact that NB is 
sometimes diagnosed in the perinatal period, no environmental 
influences as prenatal exposures that impact on disease recurrence 
have been identified consistent (Connelly et al., 2007). 
The peculiarity of this pediatric tumor is the heterogeneity: clinical 
variability and genetic abnormalities acquired by the tumor cells are at 
basis of the complex biology of NB. During the past two decades, the 
major biological and genetic features of the tumor have been 
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identified and therapeutic strategies have been proposed to treat NB. 
A deeply knowledge of the molecular mechanism of development are 
actually determinant to develop new therapy less toxic and more 
effective (Park et al., 2008; Maris et al., 2007; Brouder 2003). 
 
1.2 Pathology: Cell of origin and stem cell hypothesis 
NB are drived from precursor or immature cells of the sympathetic 
nervous system (SNS), and primary tumors can be found at any 
location of SNS structures as ganglia, paraganglia and adrenal 
medulla. 
 
 
Figure 1 Neural crest cells formation during embryonic development 
 
The sympathoadrenal lineage originates form the neural crest cells 
which appears at the dorsal edge of the neural fold at the third 
embryonic week (Figure 1). These cells migrate along define routes in 
the interstitial space of the embryo, and exposed to a variety of 
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environmental cues, they can develop into such diverse tissues or cell 
types as the peripheral nervous system, melanocytes, smooth muscle, 
cartilage, and skeletal structures of the head (Reviewed in Mora et al., 
2004).  
The SNS is composed of neurons, chromaffin cells, and small 
intensely fluorescent cells (SIF). The neurons (ganglio cells) make up 
the ganglia proper, which comprise the paravertebral sympathetic 
chain ganglia and the para-aortic trunkus and pelvic ganglia. The SIF 
cells are located in the sympathetic ganglia, either solitarily or in 
clusters, but their function has not yet been determineted. Sympathetic 
neuroblasts/ganglion cells are also present in the medulla of the 
developing human adrenal gland, but these cells apparently disappear 
during development. Chromaffin cells make up two structures: the 
paraganglia and the adrenal medulla. The paraganglia are the main 
source of catecholamines outside the central nervous system, and 
thereafter production is taken over by the adrenal gland (Reviewed in 
Mora et al., 2004). 
Recently, the cancer stem cell hypothesis has provided an intruiging 
alternative explanation for NB heterogeneity. Although the presence 
of cancer stem cells with leukemia and some solid tumors has been 
estabilished, NB stem cells have not been clearly identified (Johnsen 
et al., 2009). Notch, Sonic hedgehog, and Wnt/b-catenin pathways are 
implicated in embryonal tumorigenesis; NB stem cells arising from 
normal neural crest stem cells, could partly preserving and 
 16
dysregulating these pathways (Allenspach et al., 2002; Blanc et al., 
2005). The identification and characterization of cancer stem cells in 
NB could permit a targeted approach to more effective treatment.  
 
2. Neuroblastoma Heterogeneity 
 
2.1 Clinical presentation and staging 
Due to their neural crest cell lineage, NBs may occur in the adrenal 
medulla (most common location) or anywhere along the sympathetic 
ganglia. Additional sites of origin include the neck, chest, and pelvis. 
Mostly infants present thoracic and cervical primary sites. One 
percent of patients have no detectable primary tumor. Early 
symptoms, when present, are typically nonspecific symptoms such as 
general malaise, weight loss, and unexplained fever. In general severe 
symptoms do not occur until the tumor has reached a critical size 
and/or developed metastases (Titilope et al., 2007). 
NB diagnosis is confirmed by pathologic definition from tumor tissue 
or NB tumor cells in a bone marrow sample and by the setting of 
increased urine or serum catecholamines or catecholamine metabolites 
(dopamine, vanillylmandelic acid, and homovanillic acid) (Park et al., 
2008). 
The Shimada classification, modified as the International 
Neuroblastoma Pathology Classification (INPC),  has been widely 
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used to describe and predict NB behaviour and prognosis (Shimada et 
al., 1999). This classification system takes in consideration histologic 
features such as the degree of cellular differentiation, schwannian 
stroma and the mitosis-karyorrhesis index (MKI), in addition to the 
age of the patient. According to INPC, NB is a tumor composed of 
neuroblastic cells forming groups of nests separated by stromal stepta 
with none to limited Schwannian proliferation. However, at the time 
of diagnosis and to establish appropriate treatment protocols, the 
generally accepted method is the International Neuroblastoma Staging 
System (INSS) (Brodeur et al., 1993). 
The INSS definitions for NB stage are shown in Figure 2. Completely 
resected tumors are classified as Stage 1, and partially resected 
regional tumors with or without regional nodal involvement are 
classified as Stage 2. Stage 3 is rappresented by tumors that have 
spread across the middle of the body and present liver, bone and 
regional lymph node involvement. Stage 4 disease is defined as distant 
nodal or hematogenous spread of disease. Stage 4S is represented by 
localised primary tumor and an unique pattern of dissemination 
limited to liver, skin, and minimal bone marrow involvement. The 
tumors of Stage 4S have a potential for spontaneous regression and/or 
neuronal differentiation, even after no, or minimal therapy 
intervention, in marked contrast with the disseminated aggressive 
disease (Evans et al., 1980; Yamamoto et al., 1998). 
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Figure 2 International Neuroblastoma Staging System (INSS) 
 
2.2 Genetic Heterogeneity 
NB is a very heterogeneous tumor which present different genetic 
alterations in the population. Despite extensive data correlating 
genomic alterations with disease outcome, no bona fide target genes 
have been identified for NB, with the exception of MYCN 
(subsequently described) (Figure 3).   
Disorders resulted from abnormalities in the development of neural 
crest cells in embryo such as Hirscsprung disease, neurofibromatosis 
type 1, and congenital central hypoventilation syndrome have been 
reported in association with NB. Anyway, not specific abnormality 
has been identified with increased frequency, suggesting that NB has a 
different origin (Clausen et al., 1989; Rohrer et al., 2002; Trochet et 
al., 2005). 
Familial forms of NB are rare, accounting for about 1% of all cases.  
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The median age at diagnosis of patient with familiar NB is 9 months, 
which contrasts with a median age of 18 months for NB in the general 
population. There are two reported pedigrees of familial NB which 
show a linkage of NB predisposition to chromosomal region 16p12-
p13, found in North American families and linkage to chromosome 
12p and 2p reported in studies of European pedigrees (Maris et al., 
2002; Longo et al., 2007). 
Recently, a whole-genome linkage scan in a panel of NB pedigrees 
identified a significant linkage signal at 2p23-24. In this region 
germline mutations were identified in ALK gene (Mosse et al., 2008). 
Subsequently, in about 8% of all sporadic NB tumors, somatic ALK 
mutations or amplification were identified (Caren et al., 2008; Chen et 
al., 2008; Janoueix-lenosey et al., 2008). ALK is a member of the 
tyrosine kinase family and mutations provide a therapeutic target in 
NB (George et al., 2008). Most NBs occur spontaneously. Somatic 
changes, such as gain of  alleles and activation of oncogenes, loss of 
alleles or changes in tumour-cell ploidy have been shown to be 
important in the development of sporadic NB. 
DNA content is most prognostic in NB for patients who are 1-2 years 
old. Near-triploid NB (55%) are characterized by whole chromosome 
gains and losses without structural genetic aberrations. These tumors 
are more often localized and show a favourable outcome. Near-diploid 
NB (45%) are characterized by the presence of genetic aberrations, 
such as MYCN amplification, 17q gain, and chromosomal losses and 
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show unfavourable outcome (Brodeur 2003; Bagatell et al., 2005; 
Look et al., 1991). 
The MYCN oncogene, located on the distal short arm of chromosome 
2, locus 2p24,  is present in an increased copy number in 30% to 40% 
of stage 3 and 4 NB (Schwab et al., 1984; Weiss et al., 1997). MYCN 
oncoprotein is a transcription factor which forms heterodimers with 
MAX protein, leading to activation of gene targets ODC, MCM7 and 
MRP1 and to progression through the G1 phase of the cell cycle.  
Even if  MYCN has a short half-life, the extremely high steady-state 
levels (100 times normal) in amplified tumor cells probably ensures 
that cells stay in cycle and do not enter G0. In absence of MYCN, 
MAX forms homodimer that is transcriptionally repressive (Wenzel et 
al., 1994). 
Gain of the entire chromosome 17 or gain of parts of chromosome 17q 
occur in greater than 80% of NBs. The partial 17q gain most often 
results from unbalanced translocation of 17q21-25 to chromosome 1 
(Meddeb et al., 1996; Van Roy et al., 1994) and identifies 
unfavourable NB (Vandesompele et al., 2005). Obvious candidate 
genes on 17q are the NM23 and the BIRC5 (survivin) gene (Adida et 
al., 1998; Godfriend et al., 2002). 
Loss of tumor suppressor regions is reported in NBs for many 
chromosomal regions. The most frequently affected regions are 
chromosome 1p ( 30-40%), 4p (20%), and 14q (25%). Chromosome 
1p loss occurs more frequently in older children who have stage 3 and 
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4 NB (Gehring et al., 1995; Caron et al., 1996). In almost all samples 
with MYCN amplification, concomitant 1p loss is demonstrated, but 
loss of chromosome 1p can also occur in MYCN-single copy cases. In 
the past, many attempts were made in order to delineate a shortest 
region of deletion (SRD) on 1p36 (Okawa et al., 2008). One of the 
most promising candidate NB suppressor genes in this region is 
CHD5 (Bagchi et al., 2007; Fujita et al., 2008). This gene is a member 
of the chromatin remodelling family and is expressed mostly in the 
nervous system. Whitin region, KIF1B gene, a member of the kinesin 
3 family, was identified as a haploinsufficient candidate tumor 
suppressor gene (Munirajan et al., 2008). 
Chromosome 11q loss is demonstrated in approximately 40% of 
patients. It is inversely correlated with MYCN amplification and 
therefore identifies an additional high-risk subset of patients 
characterized by advanced stage, older age, and unfavourable 
pathology (Attiyeh et al., 2005; McArdle et al., 2004). Recently, two 
common regions of deletion on the long arm of chromosome 11 were 
delineated and CADM1 was identified as a candidate tumor 
suppressor gene (Michels et al., 2008; Nowacki et al., 2008). 
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Figure 3 Mostly frequent genetic abnormalites in Neuroblastoma 
 
Genome-wide association studies (GWASs) have shown a significant 
association between clinically aggressive NBs and common single 
nucleotide polymorphism (SNPs) or variants at chromosome region 
6p22 (Maris et al., 2008). A second susceptibility locus for the 
development of aggressive NB tumors was identified, BARD1 locus 
at 2q35. This susceptibility is linked to six SNPs located in introns 1, 
3 and 4 of BARD1 (Capasso et al., 2009). The BARD1 protein 
heterodimerizes with the familial breast cancer gene product BRC1 
and is essential for the tumor suppressor activity of BRC1 (Wu et al., 
1996). 
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2.3 Tumor Biology 
 
A number of biological pathways regulating cancer seem to be 
distrupted or affected in NB, including tumor differentiation, 
apoptosis, drug resistence, angiogenesis, and metastasis. Insight into 
the molecular regulation of these biological pathways will lead to the 
identification of novel drug targets.  
NB has the highest rate of spontaneous regression observed in human 
cancers, so delayed activation of normal apoptotic pathways might be 
important phenomenon involved in spontaneous regression and 
therapy resistance. Major elements of apoptotic signalling cascade 
with abnormal expression include BCL2 family, survivin and caspase 
8. BCL2 is highly expressed in most NBs, and the level of expression 
is inversely related to the proportion of cells undergoing apoptosis and 
the degree of cellular differentiation. The BCL2 protein might also be 
important to acquire resistance to chemotherapy (Castle et al., 1993). 
Caspase-8 is mainly affected by inactivation due to epigenetic 
silencing. CpG-island hypermethylation of gene promoters is a 
frequent mechanism for functional inactivation of genes. In NB, this 
mode of inactivation has been demonstrated not only for caspase 8 but 
also for the four TRAIL apoptosis receptors, the caspase-8 inhibitor 
FLIP, the RASSF1A tumor suppressor, p73, RB1, DAPK, CD44, 
p14ARF, and p16INK4a (Eggert et al., 2001; Hopkins-Donaldson et 
al., 2000; Teitz et al., 2000).  Because many of these genes are 
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involved in apoptotic signalling and therapy responsiveness, gene 
hypermethylation might be a major event leading to resistence. 
Therefore, the antitumor effects of demethylating agents, including 
decitabine, are being investigated in preclinical studies. 
Acquired resistence to chemotherapeutic agents may be conferred by 
enhanced drug efflux due to overexpression of classical multidrug 
resistence proteins, including multidrug resistence gene 1 (MDR1) 
and the gene for multidrug resistance-related protein (MRP1) whose 
potential clinical significance in NB has been addressed in several 
studies (Goldstein et al., 1990; Haber et al., 2006). 
Several additional factors have been shown to contribute to the 
treatment resistance in NB, including the expression of oncogene such 
as MYCN, TrkB/BDNF signalling, or loss of p53 expression (Jaboin 
et al., 2002). 
Neurotrophin signalling mediated by neurothrophin tyrosine kinase 
receptors TrkA, TrkB and TrkC and the ligands NGF (nerve growth 
factor), BDNF (brain derived nerve factor), NT3 (neurotrophon 3), 
respectively, has a central role in normal neuronal development 
(Nakagawara et al., 1994;1993). 
Alterations of these pathways have been found to be responsible of 
regulating the differentiation or the malignant transformation of 
sympathetic neuroblasts to NB. Since the clinical and biological roles 
of Trk receptors and their ligands have been extensively investigated, 
they have been identified as important prognostic factor in NB. High 
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expression of TrkA was correlated with younger age, lower stage and 
absence of MYCN amplification. Furthermore, TrkA levels was 
correlated with favourable outcome and a combination of TrkA 
expression and MYCN amplification provided even greater prognostic 
power. By contrast, full-length TrkB expression was strongly 
associated with MYCN amplified tumors. Because these tumors also 
present high level of ligand BDNF, this might present an outcome or 
paracrine loop, thereby providing some survival and growth advantage 
(Nagakawara et al., 1993, 1994). 
NB aggressive phenotype correlates to high expression of important 
players of tumor adhesion and migration such as CD44 and NM23-
H1, and of regulators of local invasiveness and metastasis such as 
metalloproteinases (mainly MMP9) (Gross et al., 2000; Almgren et 
al., 2004; Chantrain et al., 2004). High expression of proangiogenic 
factors such as vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF) which enhance tumor angiogenesis, 
are   also correlated with more aggressive phenotype (Ribatti et al., 
2004). These observations make angiogenesis and invasion inhibitors 
an attractive treatment option that is being evaluated in preclinical 
studies.  
During the past decade, one set of small-non-coding RNAs (miRNA) 
has been studied heavily in the contest of cancer. Their expression 
correlates to prognosis, diagnosis and response to treatment and, like 
coding genes, they can function as oncogenes or tumor suppressor 
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genes. Overexpression of the miR-17-92 cluster has been reported in 
several cancer and is responsible of cycle progression and blocking of 
apoptotic signalling (Hayashita et al., 2005). In NB miR-17-92 cluster 
expression is directly activated by MYCN through a direct binding to 
conserved E-box elements in miR-17-92 promoter. Treatment with 
antagomir-17 abolished the growth of MYCN-amplified and therapy-
resistant NB in vivo, indicating that targeting miR-17-92 is useful in 
the treatment of NB (Fontana et al., 2008). 
 
3. NB therapy 
 
Current treatment for high-risk NB consists of a coordinated sequence 
of chemotherapy, surgery, and radiation (Matthay et al., 1999). 
Over half of children presenting NB have widespread metastatic 
disease. Although the majority of these children respond well to 
intensive chemotherapy, with complete remission of metastatic 
disease in many cases, most appear to harbour occult minimal residual 
disease which eventually results in disease relapse. Although outcome 
has improved with intensive multimodal treatment protocols, 
prognosis remains poor with long-term survival in only around 30-
40% of children with high-risk disease. Several rationally chosen 
biologic agents are in ongoing clinical trials for recurrent NB, 
including histone deacetylase inhibitors, Trk tyrosine kinase 
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inhibitors, and anti-angiogenic agents, to optimize treatment of 
minimal residual disease. 
Immunotherapy is an attractive therapeutic option for NB as it 
potentially offers a much more specific and less toxic treatment than 
conventional therapies. The genetic alterations in cancer cells that 
confer upon them their malignant properties also result in the 
expression of proteins, or tumor antigens, that differ from normal cells 
and have the potential to be identified by the immune system as 
foreign (Boon et al., 1997). GD2 glycosphingolipid is abundantly 
expressed on the cell membranes of virtually all human NB cells, 
providing a good target for mAb targeted therapies. To date, three 
monoclonal antibodies direct against GD2 have been used clinically in 
children with NB, showing most promise when used in children with 
minimal residual disease (Modak et al., 2007). 
The efficacy of isotretinoin (cis-RA) in treating minimal residual NB 
has been demonstrated, establishing a standard use of non cytotoxic 
therapy. Alternative retinoid derivatives, including fenretinide, have 
been tested and show promising response rates in recurrent disease 
(Matthay et al., 1999). 
 
3.1 Retinoic Acid 
Retinoic Acid (RA) is a derivate of Vitamin A (retinol) belonged to a 
Retinoid family, which can exist in alternate stereoisomeric forms 
(all-trans, 9-cis or 13-cis). Retinol is usually ingested and up-taken by 
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a system involving retinol binding protein (RBP) and the 
transmembrane protein STRA6 (Kawaguchi et al., 2007).  During 
animal development, RA is synthesized from retinol in two steps of 
NAD-dependent oxidation, each catalyzed by different families of 
enzymes. The first step is the reversible oxidation from retinol to 
retinal by the alcohol dehydrogenases (ADH) which can metabolize 9-
cis and 13-cis retinol as well as all-trans retinol, and by the short-chain 
dehydrogenases/reductase (SDR) which can only catalyze the 
oxidation of all-trans retinol (Yaung et al., 1994). The second step is 
the irreversible oxidation of retinal to retinoic acid (RA) by the 
aldehyde dehydrogenase family (ALDH) (Duester et al., 1996). Other 
proteins, such as cellular retinoid binding proteins (CRBP) interact 
with retinoids regulating the availability of RA in vivo and mediating 
the transport of RA to the nucleus (Napoli et al., 1999). The 
availability of RA is also controlled through its degradation by 
proteins of the cytochrome P450 which catalize the oxidation of RA in 
a wide range of metabolites whose biological activity is controversial 
(White et al., 1997). RA functions are mediated by heterodimers of 
two members of the nuclear hormone receptors superfamily-RAR and 
RXR (reviewed in Gronemeyer et al., 2004) (Figure 4). 
Co-activators and co-repressors also regulate the activity of RA. Many 
co-activators such as CBP/p300 and pCAF contain histone 
acetyltransferase activity, able to remodel chromatine to a more open 
conformation, allowing assembly of large protein complexes with the 
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basal transcription machinery (Kamei et al., 1996; Blanco et al., 
1998). The heterodimers binds to specific DNA elements in the 
regulatory regions of target genes, called RA response elements 
(RAREs). In vitro, RAR can bind both all-trans and 9-cis RA, whereas 
RXR can only binds 9-cis RA. During embryonic development, RA 
activities is to regulate transcription of two classes of gene targets: 
genes coding for factors involved in the RA pathways (synthesis, 
metabolism and signalling)  and transcription factors containing 
homeobox domains crucial in the developing embryo. RA has long 
been thought to act over distance in the form of gradient along the 
anteroposterior (AP) body axis in the vertebrate embryo: high 
concentrations in the posteriormost part of the embryo activate a 
specific group of genes whereas low concentrations in the anterior 
part active other genes (Chen et al., 1994). The responsiveness to RA 
depends on the sensitivity of given tissue which varies both 
temporally and spatially during development.  
Alteration of RAR expression or function has been observed in a 
variety of cancers. In the case of acute promyelocytic leukemia, it has 
been shown that a major cause of this disease is a genetic 
translocation resulting in the production of a fusion protein containing 
RARalpha (Pandolfi et al., 2001). In some tumors, RA can induce the 
expression of RARbeta, and this is associated with growth 
suppression. However in many tumors RARbeta is silenced either 
 30
through deletion, mutation or methylation within the promoter 
sequence (Nkayama et al., 2001). 
 
 
Figure 4. Retinoic Acid: Mechanism of Action 
 
It has also been shown that retinoic acid can restore “normal” 
functions (differentiation) in certain tumors, such as NB (Sidell et al., 
1982), melanoma (Ludwig et al., 1980) and acute promyelocytic 
leukemia (PML) (Breitman et al., 1980). 
In NB cell lines RA induces differentiation up-regulating the 
transcription factor AP-1 and by activating JNK pathway via MAP 
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kinase which is required for neurite outgrowth (Huang et al., 2003; Yu 
et al., 2003). RA also activate Erk1/2 pathway in SHSY5Y NB cells 
during neuronal differentiation and alter the activity of the 
phosphoinositide-3 kinase/Akt pathway which is associated with 
enhanced cell survival (Singh et al., 2003; Lopez-Carballo et al., 
2002). One of the major biological effects of RA is to inhibit cell 
proliferation, by inhibiting cyclin D and stimulating p27 expression 
which block progression through the G1 phase of the cell cycle (Zhou 
et al., 1997). 
In clinical practice, all-trans retinoic acid (ATRA) is mainly used for 
patients with acute PML (Huang et al., 1989). In the treatment of NB 
patients, ATRA has been used as a chemotherapeutic agent with same 
success (Reynolds et al., 2003), but 13cis-RA is preferred due to its 
more favourable pharmacokinetics (Veal et al., 2002; Reynolds et al., 
1994; Matthay et al., 1999) . Furthermore, studies comparing the 
activities of 13cis-RA and ATRA in NB cell lines have demonstrated 
similar potencies of these retinoids, in terms of cellular differentiation, 
growth arrest and regulation of tumour markers such as MYCN (Yuza 
et al., 2003). 
 
4. Neurothrophin receptors 
 
The family of neurotrophin tyrosine kinase (NTK) receptors consists 
of TrkA (NTRK1), TrkB (NTRK2), and TrkC (NTRK3). The primary 
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ligands for these receptors are nerve growth factor (NGF), brain 
derived neurotrophic factor (BDNF), and neurotrophin-3 (NT3), 
respectively; neurotrophin-4/5 (NT4) functions through TrkB (Kaplan 
et al., 1991a, 1991b; Klein et al., 1991a, 1991b) (Figure 5). Although 
TrkC is the primary receptor for NT3, it also binds and activates TrkA 
and TrkB. Another transmembrane receptor (P75) binds all the 
neurotrophins with low affinity. P75 can interact directly with TrkA, 
TrkB, and TrkC in both extracellular and intracellular domains, and 
this interaction may contribute to the formation of high-affinity 
receptors or otherwise alter the function of Trk receptors 
(Hantzopoulos et al., 1994).  
Trk expression is crucial for the normal development of the peripheral 
nervous system. Knockout mice for TrkA, TrkB, or TrkC display 
unique but overlapping patterns of abnormalities involving the central 
and peripheral nervous system, but the TrkB knockout is the most 
severe (Klein et al., 1994, 1993; Smeyne et al., 1994). Nevertheless, 
TrkA expression is most important for the development of normal 
sympathetic neurons (Fagan et al., 1996; Schober et al., 1997). Indeed, 
NGF is necessary for the survival and differentiation of sympathetic 
neurons both in vitro and in vivo (Levi-Montalcini, 1987). For 
sympathetic neurons, TrkC (±TrkA) is expressed early, TrkB 
expression is rarely if ever seen (Dixon et al., 1994; Schober et al., 
1997), and TrkA expression predominates in later stages. 
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Figure 5 Trk receptors and ligands 
 
TrkA, TrkB, and TrkC have distinct isoforms that affect the function 
of the receptors. The neuronal TrkA isoform (TrkA-I) lacks exon 9 
(790 aa), whereas TrkA-II nonneuronal isoform is 796 aa, and has 
enhanced responsiveness to NT3 (Clary et al., 1994). There is also an 
early developmental form (TrkAIII) that splices out exons 6, 7, and 9 
and is constitutively active independent of ligand. TrkB is expressed 
as both full-length (kinase-intact) and truncated (kinase-deleted) 
isoforms (Nagakawara et al., 1995; Allen et al., 1994; Middlemas et 
al., 1991). Both may act as dominant-negative inhibitors of full-length 
TrkB kinase activity, because expression of truncated TrkB receptors 
inhibits BDNF-induced neurite outgrowth (Fryer et al., 1997). TrkC 
also has full-length and truncated isoforms, similar to those found for 
TrkB (Menn et al., 1998). 
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Upon binding of their specific ligands, Trk receptors dimerize and 
autophosphorylate cytoplasmic tyrosines. Signal transduction is 
processed through a diverse array of signaling pathways, including the 
Ras/MAPK-, the inositol (1,4,5) triphosphate (IP3)-dependent Ca2C 
release and the PI3K/AKT pathway (Kaplan et al., 1997). Ras/MAPK 
are activated downstream of TrkA pathway. MAPK translocates to the 
nucleus to participate in the activation of transcription factors that 
regulate NGF-inducible genes, resulting in survival and neuronal 
differentiation. Activated TrkB receptor recruits PI3K via adaptor 
proteins such as Shc and Gab-1. Alternatively, PI3K can be activated 
downstream of Grb2-binding or of Ras G-proteins. PI3 kinase activity 
is critical for TrkB receptor-mediated survival signalling (Fryer et al., 
1997) utilizing lipid second messengers that activate the serine 
threonine kinase Akt, also known as protein kinase B (PKB) (Figure 
6). 
Critical elements of the Trk signaling pathway may vary between 
different tissues leading to a cell-type-specific response. For example, 
stimulation of TrkA by its specific ligand, nerve growth factor (NGF), 
leads to differentiation of neurons and NB cells, whereas it induces 
proliferation of fibroblasts and apoptosis of medulloblastoma cells 
(Muragaki et al., 1997; Micera et al., 2001). In contrast to its role in 
NB, TrkB is associated with a favorable biology and good prognosis 
in medullary thyroid carcinoma (McGregor et al., 1999). 
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Figure 6 Transduction signals of Trk receptor  
 
4.1  Biological role of Trk receptors in neuroblastoma 
In order to understand complex regulation patterns via tyrosine 
receptor TrkA or TrkB signalling in NB,  pathways and the resulting 
phenotypes have been well studied in stable Trk-expressing SY5Y 
cells (Eggert et al., 2000, 2002). 
From the reported observations in these cellular models, activation of 
TrkA by NGF resulted in neuronal differentiation, growth inhibition, 
inhibition of angiogenesis and sensitization to drug-induced apoptosis 
(Eggert et al., 2000, 2002). Whereas, activation of TrkB by its ligand 
brain-derived neurotrophic factor (BDNF) mainly resulted in 
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enhanced proliferation and chemotherapy resistance of the cells (Ho et 
al., 2002). The biological phenotype of the transfectants corresponds 
well with the excellent prognosis of primary neuroblastomas 
expressing high levels of TrkA, and the poor prognosis of 
neuroblastomas expressing TrkB. These models represent the starting 
point to clarify the molecular basis of aggressiveness in NB.  
 
5. Galectin-1 
 
Galectins are conserved family of lectins, carbohydrate binding 
proteins with an affinity for beta-galactoside. Fifteen mammalian 
galectins have been defined to date which share consensus of amino-
acid-sequences and are composed of one or two  carbohydrate 
recognition domain (CRD) responsible for beta-galactoside binding. 
Regarding to biochemical structure, some galectins contain one CRD 
and exist as monomers (galectin-5, -7, -10) or as homodimers 
(galectin-1, -2, -11, -13, -14, -15) whereas other galectins contain two 
CRD connected by a short linker region (galectin-4, -6, -8, -9, -12). In 
contrast, galectin-3 uniquely occurs as chimeric protein with one CRD 
and a non-lectin domain involved in oligomerization of this protein. 
CRD of all galectins share an affinity for the N-acetyl-lactosamine, 
but different modifications to this minimum disaccharide ligand can 
also be recognised, showing the fine specificity of certain galectins for 
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tissue- or developmentally-specific ligands (Reviewed in Rapoport et 
al., 2008) (Figure 7). 
 
 
Figure 7 Galectins Family 
 
Galectin-1 (Gal-1) is encoded by the LSGALS1 gene located on 
chromosome 22q12. The homodimeric Gal-1 protein can 
spontaneously dissociate at low concentrations into a monomeric form 
that is still able to bind to carbohydrates but with a lower level of 
affinity. 
Gal-1 shows the characteristics of typical cytoplasmic proteins as well 
as an acetylated N-terminus and a lack of glycosylations. It has been 
described in cell nuclei and cytosols and it also translocates to the 
intracellular side of cell membranes. Gal-1 is secreted and can be 
found on the extracellular side of all cell membranes as well as in the 
extracellular matrices of various normal and neoplastic tissues. Gal-1 
lectin activity, related to its carbohydrate-binding site, is observed 
when it is extracellular, whereas the protein-protein interactions of 
Gal-1 concern its intracellular functions (Reviewed in Rabinovich 
2005).  
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Expression of Gal-1 has been well documented in many different 
tumor types including astrocytoma, melanoma and prostate, thyroid, 
colon, bladder and ovary carcinomas. Interestingly, in most cases such 
expression correlates with the aggressiveness of these tumors and the 
acquisition of metastatic phenotype (reviewed in Liu and Rabinovich 
2005; Rabinovich 2005; Salatino et al. 2008) (Figure 8). 
Intracellular Gal-1 may play a key role in the initiation of transformed 
phenotype of tumors. It has been found that Gal-1 interacts with 
oncogenic H-RAS and contribute to membrane anchorage of H-RAS. 
Furthermore, in tumor cells both the membrane association of H-RAS 
and cell transformation are increased by over-expression of Gal-1. 
Intracellular Gal-1 causes biphasic modulation of cell growth, 
depending on the dose involved. In NB and stromal bone marrow cells 
high doses of recombinant Gal-1 (1uM) inhibit cell proliferation 
independently of Gal-1 sugar binding activity; low doses (1nM) of 
Gal-1 are mitogenic and are susceptible to inhibition by lactose. The 
paradoxical positive and negative effects of Gal-1 on cell growth are 
highly dependent on cell type and cell activation status, and might 
also be influenced by the relative distribution of monomeric versus 
dimeric, or intracellular versus extracellular forms. 
Extracellular Gal-1 has an important role to modify adhesion, motility, 
and invasion processes. Gal-1 increases the adhesion of various 
normal and cancer cells to the extracellular matrix via cross-linking of 
glycoproteins (integrins) exposed on the cell surface (Hughes, 2001). 
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Gal-1 causes the increased motility of glioma cells and the 
reorganization of the actin cytoskeleton associated with an increased 
expression of RhoA protein (Yamaoka et al., 2000). An important role 
of Gal-1 is the function as a homeostatic agent by modulating innate 
and adaptative immune responses (Juszynski et al, 2007; Rodig at al, 
2008). The effects of Gal-1 on immune and inflammatory cells are 
likely to be due to the binding and cross-linking on the cell surface of 
T cells of the glycoproteins as CD2, CD3, CD7, CD43 and CD45, in a 
carbohydrate-dependent manner. This binding leads to apoptosis of 
activated T cells, thus contributing to tumor immuno-escape (He and 
Baun, 2004)..  
 
Figure 8 Galectin-1 and cancer progression 
 
Taken in account the association of high expression of Gal-1 to tumor 
progression, it still remains to be elucidated how expression of Gal-1 
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in tumor tissue or tumour-associated stroma may actively influence 
disease outcome in terms of our understanding of its multifunctional 
modes of actions.  
Drugs able to inhibit Gal-1 function have been defined. Actually 
present in clinical trials, anginex is a peptide that targets Gal-1 and 
shows an anti-angiogenic activity in vivo (Thijssen et al, 2006). 
Farnesylthiosalicylic acid (FTS) which disrupts Ras membrane 
anchorage imparing H-Ras(12V)-Gal-1 interactions (Paz et al, 2001) 
has proven anticancer activity in various model systems and is now 
proceeding to clinical development. 
A current challenge is the design of more specific and potent Gal-1 
inhibitors for therapeutic propose to be assessed in clinical practice (in 
association with cytotoxic agents) in the near future. 
 
6. Discovery of new therapeutic targets in 
Neuroblastoma by means of proteomic approach and 
functional studies. 
 
NB is a heterogeneous tumor for which biology dictases clinical 
behaviour, ranging from spontaneous regression/differentiation to 
metastatic forms with rapid progression and poor prognosis. Overall 
survival is excellent for patients who have low- and intermediate-risk 
NB with a general trend toward minimization therapy whereas less of 
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40% of high-risk NB patients survive because of the high risk of 
minimal residue disease. Actually, several rationally chosen biologic 
agents are in ongoing clinical trials for recurrent NB, including 
histone deacetylase inhibitors, Trk tyrosine kinase inhibitors, and anti-
angiogenic agents.  
The goal of this thesis has been to suggest new ways to improve the 
current therapeutic protocols as the use of low-toxic drugs 
(differentiation agents) and as impairing NB by means of targeting 
downstream mediators of the mainly involved pathways (Trk 
pathways).  
 
6.1 First Aim 
The good knowledge of the molecular mechanism of differentiation in 
NB is imperative to improve the efficacy of therapy whose targets 
could be the drivers of the differentiation program.  
Retinoids are used to treat minimal residual NB and are estabilished as 
standard for the use of noncytotoxic therapy (Reynolds et al., 1991). 
Advances in understanding the molecule biology of NB have been 
supported by the use of high-throughput, array-based methods not 
only to improve prognosis but also to identify key targets that can 
efficiently be exploited therapeutically. For example, gene expression 
profiling on NB specimens have been described as identifying the 
molecular signatures of high-risk and low-risk tumours and novel 
prognostic markers (Ohira et al., 2003, 2005; Hiyama et al., 2004; 
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Riley et al., 2004; Wei et al., 2004; Takita et al., 2004; Schramm et 
al., 2005b). Anyway, the search for markers at the transcriptional level 
is less reliable than at the protein level, as there is a “long” and 
unpredictable route from RNA to proteins, and very often protein 
expression does not correlate with mRNA expression. Indeed, several 
proteins can be encoded by the same gene, through splice variants and 
post-translational modifications that cannot be directly predicted from 
gene sequence. These observations have lead to search for markers at 
translation levels, by using a comparative proteomic approach. 
Actually, two-dimensional difference gel electrophoresis (2D-DIGE) 
coupled with mass spectrometry (MS) is the best proteomic approach, 
extensively used to identify potential biomarkers of various cancers 
(Kumar et al., 2009; Kohnke et al., 2009; Ploussard et al., 2010). 2D-
DIGE advantages over traditional 2D-PAGE are: 1) multiple pre-
labelling of samples; 2) introducing a pooled internal standard; 3) co-
detection; and 4) a wider dynamic range. In spite of this, one of the 
limitations of DIGE-based proteomics is the low identification rate of 
low-abundance proteins (Hoorn et al., 2006). 
In the first part of my thesis, my aim was to gain further insight into 
the molecular mechanisms of NB differentiation induced by ATRA, in 
order to underline which pathways and molecular markers are 
responsible of this process. I combined the advantage of 2D-DIGE 
proteomic approach to the advantages of sub-cellular fractionation. 
The sub-cellular fractionation of the proteoma in cytosol and nuclear 
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fractions gave the possibility to show a major number of proteins on 
the same gel and to enrich the low-abundant proteins in the extract.  
 
6.2 Second Aim 
Trk tyrosine kinase receptors represent the most important prognostic 
marker in NB. The expression of neurothrophin brain-derived 
neurotrophic factor (BDNF) and its tyrosine receptor TrkB are often 
detected in NB tumors derived from patients with an unfavourable 
prognosis. In the other hand, high expression of tyrosine receptor 
TrkA is correlated to favourable biological features and patient 
survival.  
Although mediators of Trk pathways have been elucidated in the past 
years, there is still to be searched the potential markers leading to the 
aggressive behaviour of TrkB expressing NB despite the TrkA 
expressing NB (Schulte et al., 2005). To elucidate markers of NB 
aggressiveness is an important step to develop effective therapy 
reducing the risk of minimal residue. In previous studies Galectin-1 
emerged as new interesting TrkB receptor target: Gal-1 mRNA was 
up-regulated in patients with aggressive, relapsing NB and protein 
was up-regulated in an in vitro model of aggressive TrkB expressing 
NB cells.  
The aim of the second part was the functional study of Gal-1, down-
stream mediator of TrkB signalling, in order to  establish Gal-1 as a 
potential therapeutic marker in high-risk TrkB-expressing NB. 
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Material and Methods 
 
1.Cell Culture 
 
1.1 Cell Culture and characteristics of stable 
transfectants  
The human LAN-5 NB cell line was grown in RPMI medium. The 
human SK-N-BE and SH-SY5Y NB cell lines were grown in 
Dulbecco’s modified Eagle’s medium. Full-length TrkB or TrkA 
cDNA was cloned into the retroviral expression vector, pLNCX, and 
transfected in human NB SH-SY5Y (SY5Y) cells by electroporation. 
Stably transfected cells were selected in RPMI medium supplemented 
with 500 mg/ml geneticin. As negative control, SY5Y cells were 
transfected with the empty vector (SY5Y-vec). Surviving, drug-
resistant SY5Y cells were subcloned to obtain single-cell clonal lines 
(Schulte et al., 2005). Cells were maintained in an atmosphere 
containing 5% CO2 in RPMI 1640 medium supplemented with 10% 
fetal bovine serum, antibiotics. The stable clones were also 
supplemeted with geneticin to maintain selection pressure. 
The cells were passaged 1:4 twice weekly and routinely fed 24 h 
before each experiment.  
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1.2 Neuronal Differentiation 
Neuronal differentiation was induced in cells at 80% confluence by 5 
µM ATRA (Sigma) dissolved in dimethyl sulfoxide (DMSO). All 
experiments were performed under dim light, and the tubes containing 
retinoids were wrapped in aluminum foil. The cells were washed three 
times in 10 mL ice-cold phosphate-buffered saline (PBS) and 
harvested 0, 8, 24, and 48 h after RA treatment, using a cell scraper. 
This time course was chosen to reflect primary or early responses of 
NB cell lines to the RA treatment. Each experiment was performed in 
triplicate. Three cellular plates for each experimental point (0, 8, 24, 
and 48 h) were harvested, pooled, and centrifuged for 5 min at 2000g 
at 4 °C. The pellets were frozen at -80 °C until sample preparation. 
 
2. Two Dimensional-differential in gel electrophoresis 
(2D-DIGE) 
 
2. 1. Cytosolic Protein Fraction Preparation 
The cell pellets were incubated on ice in ice-cold lysis buffer (250 
mM sucrose, 3 mM imidazole, pH 7.4, and 1 Mm EDTA) in the 
presence of a protease inhibitor cocktail (Complete Mini EDTA-free, 
Roche). The cellular pellets were disrupted by 8-10 passes through a 
22-guage needle, and then centrifuged at 16 000g for 20 min at 4 °C. 
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The pellets obtained were considered as the nuclear fraction, while the 
post-nuclear supernatant (PNS) contained the cytosolic fraction and 
cell membranes.  
The PNS was ultracentrifuged at 100 000g for 45 min at 4°C. The 
supernatant obtained here was used as the cytosolic fraction. The 
cytosolic fraction was solubilized in 7 M urea, 2M tiourea, 40 mM 
Tris-HCl, and 4% CHAPS and incubated for 30 min under agitation at 
room temperature. 
 
2.2 Nuclear Protein Fraction Preparation.  
The nuclear pellet obtained above was resuspended in 7 M urea, 2 M 
tiourea, 40mM Tris-HCl, pH 8.5, 0.24% Triton X-100, and 4% 
CHAPS. After 30 min of incubation at room temperature, 10 mM 
spermine was added, and the solution was incubated for 1 h at room 
temperature. The precipitated material was removed by 
ultracentrifugation at 100 000g for 45 min at 4 °C. The solubilized 
cytosolic and nuclear fractions were reduced by 5mM 
tributylphosphine (TBP) for 90 min and were alkylated by 10 mM 
iodacetamide (IAA) for 90 min, in tubes wrapped in aluminum foil. 
After, the samples were precipitated for 90 min  in a mix of 
acetone/methanol (8:1) at -20 °C and centrifuged at 13 400g for 30 
min, at 4 °C. The pellets were air-dried and solubilized in 7 M urea, 2 
M tiourea, 3% CHAPS, and 30 mM Tris-HCl. Protein concentrations 
were determined using the Bradford method (Bio-Rad). 
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2.3 Cy-Dye Labeling of Cytosolic and Nuclear Fraction 
Extracts 
The pH of the samples was adjusted to pH 8.5 with 0.1M NaOH or 
HCl. Typically, 50 µg of extract was labelled with 400 pmol Cy2 
(standard mixture of extracts), Cy3, and Cy5 (untreated and RA-
treated cells). The labelling reaction was carried out on ice in the dark 
for 30 min, and was stopped with 1 mM lysine (final concentration). 
The samples were then mixed, and supplemented with 0.5% carrier 
ampholytes pH 3-10 (Bio-Rad) and 1% bromophenol blue. The final 
volume was adjusted to 380 µL with 7 M urea, 2 M tiourea, and 3% 
CHAPS. 
 
2.4 2-D Gel Electrophoresis, Imaging, and DIGE 
Analysis.  
The immobilized pH gradient (IPG) gel strips (length, 17 cm; 
thickness, 0.5 mm), nonlinear pH gradient range (NL) pH 3-10 (Bio-
Rad) were passively rehydrated with 150 µg of tripartite-labelled 
sample (50 µg for each labelled sample and 50 µg internal standard) in 
the dark overnight. Isoelectric focusing (IEF) was carried out with a 
Protean IEF Cell (Bio-Rad), with a low initial linear voltage up to 
1000 V in 5 h, and then by applying a voltage gradient up to 10 000 V 
with a limiting current of 50µA/strip. The total voltage applied was 76 
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000 V/h for each strip, and the temperature was set to 20 °C. The 
strips were equilibrated in 6 M urea, 2% SDS, 20% glycerol, and 
0.375 M Tris-HCl (pH 8.8), for 30 min in the dark. Equilibrated IPG 
strips were transferred onto 18/20 cm 11% polyacrilamide gels, within 
low-fluorescence glass plates (ETTAN-DALT, GE Healthcare). The 
second-dimension SDSPAGE was performed using a Peltier-cooled 
DALT II electrophoresis unit (GE Healthcare) at 1 W/gel overnight. 
The gels were scanned with a Typhoon 9400 variable mode imager 
(GE Healthcare) using mutually exclusive excitation/emission 
wavelengths for Cy2 (488 nm/520 nm), Cy3 (532 nm/580 nm), and 
Cy5 (633 nm/670 nm). Images were normalized and analyzed for 
statistics, and differentially expressed spots were quantified using the 
DeCyder 5.0 software (GE Healthcare). A DeCyder differential in-
gel-analysis (DIA) module was used for pairwise comparisons of each 
sample (Cy3 and Cy5) to the Cy2 mixed standard present in each gel. 
The DeCyder biological variation analysis (BVA) module was then 
used to simultaneously match all of the protein-spot maps from the 
gels, and to calculate average abundance ratios across triplicate 
samples. Proteins with molecular masses from approximately 20-150 
kDa were resolved, and approximately 3000 spots/gel were detected 
using the DeCyder image analysis software. To avoid false positives, 
only spots with a fold change equal or above 1.3 and a p value e0.075 
(Student’s t test) were taken in account. A manual sorting based on the 
quality of the protein spots was also performed. 
 49
3 Protein Identification by MS.  
 
For preparative protein separations, 1 mg of unlabeled sample was 
used to passively rehydrate the IPG strips. The first and second 
dimension runs were conducted as described above. After 2-D 
electrophoresis, the separated proteins were visualized using the 
universal staining methods of anionic dyes (Coomassie Colloidal 
Blue; Pierce). The resolved polypeptides were fixed in 10% acetic 
acid/40% methanol solution for 12-16 h before staining. The staining 
in Colloidal Coomassie was performed for 3 days, and then the gels 
were washed three times in deionized H2O. Selected protein spots 
were excised from the gels and washed in 50 mM ammonium 
bicarbonate, pH 8.0, in 50% acetonitrile until completely distained. 
The gel pieces were re-suspended in 50 mM ammonium bicarbonate, 
pH 8.0, containing 100 ng of trypsin, and incubated for 2 h at 4 °C and 
overnight at 37 °C. The supernatants containing the resulting peptide 
mixtures were removed, and the gel pieces were re-extracted with 
acetonitrile. The two fractions were then collected and freezed. 
 
3.1. MALDI MS Analysis.  
MALDI mass spectra were recorded on an Applied Biosystem 
Voyager DE-PRO mass spectrometer equipped with a reflectron 
analyzer and used in delayed extraction mode. One microliter of 
peptide sample was mixed with an equal volume of R-cyano-4-
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hydroxycynnamic acid as matrix (10 mg/mL in 0.2% trifluoroacetic 
acid (TFA) in 70% acetonitrile), applied to the metallic sample plate, 
and air-dried. Mass calibration was performed using the standard 
mixture provided by the manufacturer. Mass signals were then used 
for database searching using the MASCOT peptide fingerprinting 
search program (Matrix Science, Boston, MA), available on the 
Internet. 
 
3.2. LC-MS/MS Analysis.  
The unknown protein spots from peptide mass fingerprinting were 
further analyzed by LC-MS/MS using a Q-TOF Ultima hybrid mass 
spectrometer (Micromass, Waters) equipped with a Z-spray source 
and coupled online with a capillary chromatography system (CapLC, 
Waters). The peptide mixture (10 µL) was first loaded onto a reverse 
phase trap-column (Waters) at 10 µL/min using 0.2% formic acid as 
eluent. The sample was then transferred to a C18 reverse-phase 
capillary column (75 µm, 20 mm) at a flow rate of 280 nL/min and 
fractionated using a linear gradient of running buffer B (0.2% formic 
acid in 95% acetonitrile) in running buffer A (0.2% formic acid in 5% 
acetonitrile) from 7% to 60% in 50 min. The mass spectrometer was 
set up in the data-dependent MS/MS mode to alternatively acquire a 
full scan (m/z acquisition range from 400 to 1600 Da/e) and a tandem 
mass spectrum (m/z acquisition range from 100 to 2000 Da/e). The 
three most intense peaks in any full scan were selected as precursor 
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ions and fragmented by collision energy. Raw MS and MS/MS spectra 
were elaborated by the ProteinLynx software, provided by the 
manufacturers that generated a peak list containing all of the 
fragmentation data that was used for database searching using the 
MASCOT MS/MS ion search software for protein identification. 
 
3.3 Protein Identification by Bionformatic Tools  
Raw data from nanoLC-ESI-MS/MS analyses were converted into a 
Mascot format text to identify proteins by means of a Mascot software 
version 2.1 in home, MatrixScience.30 The protein search both from 
nanoLC-ESI-MS/MS and MALDI MS analyses was governed by the 
following parameters: nonredundant protein sequence data base 
(NCBInr -20061017 database with 4 051 787 sequences and 1 396 
484 404 residues downloaded; Sprot- 50.9 database with 235 673 
sequences and 86 495 188 residues downloaded); specificity of the 
proteolytic enzyme used for hydrolysis (trypsin); taxonomic category 
of the sample (Homo sapiens); no protein molecular weight was 
considered; up to 1 missed cleavage; cysteines as S-
carbamidomethylcysteines; unmodified N- and C-terminal ends; 
methionines both unmodified and oxidized; putative pyroGlu 
formation by Gln; precursor peptide maximum mass tolerance of 150 
ppm and a maximum fragment mass tolerance of 100 ppm. 
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4. Data Mining.  
 
Hierarchical cluster analysis was performed using a tool available on 
the Internet (http://gepas.bioinfo.cnio.es/). The distance between 
protein expression profiles was calculated using Correlation 
Coefficient (linear), and the UPGMA algorithm was used to construct 
dendrograms.35,36. The proteins were classified according to the 
DAVID 2.1 beta annotation system 
(http://david.niaid.nih.gov/david/ease.htm). This tool adopts the Fisher 
exact test to measure the protein enrichment in annotation terms. A 
Fisher exact test P=0 represents perfect enrichment. If the P-value is 
equal to or smaller than 0.05, a protein would be considered strongly 
enriched in the annotation categories. 
 
5. Western Blotting.  
 
Cells were washed three times with ice cold PBS and scraped into 
extraction buffer (50 mM Tris-HCl, pH 7.5, 150mMNaCl, 1% (v/v) 
Triton X-100, 10% (v/v) glycerol, and complete protease inhibitor 
cocktail (Roche)), transferred to 1.5 mL microcentrifuge tubes, 
vortexed for 15 min at 4 °C, and centrifuged at 16 100g for 30 min at 
4 °C. Proteins extract concentrations were determined by the Bradford 
assay (Bio-Rad). Thirty micrograms of total protein lysates was 
diluted 1:1 with Laemmli SDS-PAGE sample buffer, loaded onto 12% 
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polyacrylamide gels, and blotted onto polyvinylidene difluoride 
membranes (PVDF; Bio-Rad). Membranes were blocked with 5% 
non-fat milk (Bio-Rad) in PBS, pH 7.6, and 0.2% Tween-20 (PBS-T), 
and then incubated with specific commercial goat anti-PRX II 
(peroxyredoxin-2), SgII (secretogranin II), NF-L (68 kDa 
neurofilament), EF-2 (elongation factor-2), prefoldin subunit 3 and 
Gβ2 (guanine-nucleotide-binding protein beta subunit 2) antibodies, a 
mouse anti-PCNA (proliferating cell nuclear antigen) antibody (1:100) 
(Santa Cruz Biotechnology, Santa Cruz, CA), and a rabbit anti-EF1R 
(eukaryotic elongation factor) antibody (1:100) (Upstate) at 4 °C 
overnight. Antihuman Gal-1 goat polyclonal antibody (R&D Systems, 
Wiesbaden, Germany) was used 1:200. After a washing step in PBS-
T, the membranes were incubated with a horseradish peroxidase 
(HRP)-conjugated antigoat, anti-mouse, anti-rabbit antibody (1:10 
000) (Santa Cruz Biotechnology), and the immunoblots were 
visualized using ECL detection kits, with enhanced 
chemiluminescence (Pierce). A mouse β-actin antibody (1:1000) 
(Santa Cruz Biotechnology, Santa Cruz, CA) and mouse monoclonal 
anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) antibody 
(1:2000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used 
as the control for equal loading. The protein bands images on X-ray 
films were acquired with the GelDoc 2000 system (Bio-Rad). The 
densitometric measurements were performed by Quantity One 4.5 tool 
(Bio-Rad). 
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6. siRNA transfection  
 
Cell lines were transiently transfected with siRNAs directed against 
Gal-1 or with an unrelated control siRNA (NTC) using lipofectamine 
buffer according to the manufacturer’s protocol (Qiagen, Hilden, 
Germany). An ALEXA-labeled scrambled siRNA (Qiagen) was used 
to control for transfection efficiency and as a control for Gal-1-
mediated effects. Untreated cells and cells transfected with 
lipofectamine buffer only were included as negative controls. Cells 
were plated at 2x105 per well onto six-well plates or at 10x105 onto 
twenty-four-well plates (Corning, Lowell, MA, USA) on the day 
before transfection. The siRNA was transfected at day 1, and total 
RNA and protein were extracted at day 4. The knockdown efficacy 
was monitored by reverse transcriptase PCR and by western blotting. 
 
7. Cell proliferation analysis 
 
Ten thousand cells per well were seeded in 96 multiwell plates. After 
24 h, the cells were treated with the respective neurotrophins (NGF 
100 ng/ml, BDNF 50 ng/ml), or rGal-1 (2 mg/ml) (rGal-1 was a gift of 
Juergen Kuhlmann (Max-Planck- Institute, Dortmund, Germany)). 
Metabolic activity as a surrogate marker for cell proliferation of 
treated samples was assessed after 24 h using the MTT (3-(4,5-
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dimethylthiazol-2-yl), 5-diphenyltetrazolium bromide) assay. Cell 
vitality of siRNA-transfected cells was assessed 72 h after 
transfection. Each value represents six replicates, and each experiment 
was repeated at least two times. 
 
8. Reverse transcriptase PCR and microarray analyses 
 
Microarray experiments and analyses were performed previously 
(Schulte et al., 2005). Total RNA from 102 primary, untreated NB 
tumor samples was prepared using Qiagen RNeasy Mini Kit (Qiagen, 
Hilden, Germany). Reverse transcription, labelling of total RNA and 
subsequent hybridization to Affymetrix U133v2 chips according to 
manufactures.  
Total RNA from NB cell lines was prepared using Qiagen RNaeasy 
Mini Kit (Qiagen). cDNA synthesis was performed by standard 
protocols. Relative quantification of Gal-1 mRNA expression was 
achieved using Taqman Assay Hs00355202_m1 (Applied Biosystems, 
Foster City, CA, USA) and the DCt method. All assays were carried 
out in triplicate. mRNA expression was normalized to the averaged 
GAPDH expression in each sample. 
 
9. Cell invasion assay 
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Cell invasiveness was determined using Matrigel invasion chamber 
inserts (24-well format with 8 mm pores, BD Biosciences, Heidelberg, 
Germany). Eighty thousand cells were seeded onto the upper chamber 
in RPMI 1640 medium containing 5% fetal calf serum. siRNA-
transfected cells were seeded at day 4 after transfection. The medium 
in the lower chamber contained15% fetal calf serum in RPMI1640 
with or without the respective neurotrophins (NGF 100 ng/ml, BDNF 
50 ng/ml). rGal-1 (2 mg/ml) or anti-Gal-1 neutralizing antibody 
(1:500) or isotype immunoglobulin-G control were added once at the 
beginning of the experiment to the upper compartment. Cells 
migrating to the lower membrane surface were stained with 
hematoxylin/eosin after 24 h. Cells were counted in three 
representative areas per membrane at 40x magnification using a light 
microscope. The experiments were carried out in duplicate and two 
independent sets of experiments for each type of invasion assay were 
carried out. 
 
10. Cell migration assay 
 
A total of 100 000 cells were plated in 24-well tissue plates and 
maintained in RPMI medium. At 80–90% confluence, the tip of a 
micropipette was used to create a linear scratch resulting in two cell 
fronts that were 2mm apart from each other. The cells were washed 
with phosphate-buffered saline to remove floating cellular debris and 
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fed for an additional 24 h with either RPMI medium only or RPMI 
medium supplemented with the appropriate neurotrophins (NGF 100 
ng/ml, BDNF 50 ng/ml). Cell migration was judged by photographs 
taken immediately after scratching and at designated times after 
scratching using a digital camera. 
 
11. Immunohistochemistry 
 
After antigen retrieval, immunohistochemical stainings were carried 
out on 4 mm sections with a Techmate 500 immunostainer (DAKO, 
Glostrup, Denmark). Gal-1 antibody was used at a dilution of 1:500. 
The antigen–antibody binding was visualized by means of the avidin–
biotin complex (ABC method) using AEC (3-amino-9-ethylcarbazol) 
as chromogen. Immunoreactions were visualized with the ABC 
complex diluted 1:50 in phosphate-buffered saline (Vectastain, 
Vector, Burlingame, CA, USA). Gal-1 immunostaining was evaluated 
using a semiquantitative scoring system. Briefly, the Gal-1 staining 
intensity of NB cells (in NB) and ganglionic cells (in 
ganglioneuromas) was assessed and scaled 0–3 (0=no expression, 
1=weak expression, 2=moderate expression and 3=strong expression). 
All slides were reviewed independently by two examiners in a blinded 
manner. 
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Results 
 
1. DIGE Analysis of Differentially Expressed Proteins 
following ATRA Treatment in the LAN-5 NB Cell Line 
 
To determine the molecular mechanisms involved in ATRA-induced 
differentiation in NB, I examined changes in the proteome of LAN-5 
NB cells.  
 
1.1 Subcellular fractionation  
I analyzed LAN-5 cells proteome in two different cellular fractions, 
enriched in either cytosolic or nuclear proteins. I checked the quality 
of these fractions by Western blotting using specific markers (Figure 
9). The biochemical protein markers for nuclei included lamin β (LM 
β), which is a marker of structural components of the nuclear matrix, 
and the transcriptional factor SP1, which is a marker of the soluble 
nuclear fraction. LMβ and SP1 were mostly detected in the nuclear 
fraction; on the contrary, the cytosolic biochemical protein marker 
enolase (ENO) is mostly present in the cytosolic fraction, and only 
seen at low levels in the nuclear extract (Figure 9A).  
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Figure 9. Checking the cytosol and nucleus protein fractions. Western blotting 
was performed to test the cross-contamination of cytosolic (lane 1) and nuclear 
(lane 2) protein extracts from the LAN-5 NB cell line. The biochemical protein 
markers used for the nuclei were anti-LMβ and anti-SP1 antibodies, and an anti-
ENO antibody was used for the cytosolic fraction (A). Anti-cytochrome P450 and 
anti-LAMP-2 proteins were used as marker of mitochondria and lysosomes, 
respectively (B). 
 
To checked the enrichment of some organelles, I used cytochrome 
P450 reductase as a marker of mitochondria and lysosome-associated 
membrane glycoprotein 2 (LAMP-2) as a marker of lysosomes. I 
observed that the nuclear fraction was also enriched in these 
organelles (Figure 9B). 
 
1.2 Two-Dimensional Differential In-Gel Electrophoresis 
(2D-DIGE) analyse 
The differential expression of the LAN-5 cytosolic and nuclear 
proteins as a function of ATRA treatment was analyzed at 8, 24, and 
48 h of ATRA treatment using DIGE in a pH range of 3.0-10.0. The 
samples were labelled according to the scheme shown in Table 1. To 
increase biological and statistical significance of the results, I 
prepared the protein lysates from three independent treatments of 
LAN-5 NB cultures. Accordingly, each experiment required two sets 
of gels (see Table 1). 
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Table 1 Experimental Design of 2D-DIGE. 
 
 
The protein extracts to compare were pre-labelled with either Cy3 or 
Cy5 fluorescent dyes. Each Cy3/Cy5-labeled sample pair was co-
mixed with a Cy2-labeled pooled standard sample containing an equal 
amount of all 12 samples analyzed both for cytosolic and nuclear 
fractions. The Cy2/Cy3/Cy5 labelled samples run together on the 
same gel. Furthermore, I interchanged the labelling design in the third 
experiment to reduce the effects of preferential binding of dyes to 
proteins. For each gel, the Cy3, Cy5, and Cy2 images were imported 
into the DeCyder DIA (difference in-gel analysis) module to reveal 
the differentially expressed protein spots featured in each gel. 
To identify the differentially expressed protein spots across the six 
gels, both for cytosolic and nuclear fractions, the results from the 
intra-gel comparison (six DIA files) were imported into the BVA 
module of DeCyder Software. For the cytosolic and nuclear fractions, 
one Cy2 image was selected as the master image, and the other five 
internal standard images were matched sequentially to it (Figure 10). 
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Approximately, 3000 protein spots were detected for both the 
cytosolic and the nuclear fractions. The protein spots were then 
filtered for the statistically relevant trend of regulation (pvalue 0.075; 
Student’s paired t test) among the various ATRA treatment time 
points used. The analysis allowed us to find 126 statistically relevant 
and differentially expressed spots: 58 from the cytosolic fraction, and 
68 from the nuclear fraction, with fold changes >1.3 or e1.3 (48 vs 0 
h). In particular, 24 spots were more highly expressed and 34 spots 
were less expressed in the cytosolic fractions, with 43 spots and 25 in 
the nuclear fractions, respectively. 
 
Figure 10. 2D-DIGE gel images. Isoelectric focusing was performed on 
immobilized pH gradient IPG gel strip, NL pH 3-10, and the proteins were further 
separated by 11% SDS-PAGE in the second dimension. (A) Overlaid images of Cy3- 
and Cy5-labelled cytosolic protein extracts; and (B) as for A, for a nuclear protein 
extracts. 
 
1.3 Hierarchical Clustering Analysis 
The RA-induced proteome changes were classified on the basis of the 
expression profiles of these 126 protein spots using hierarchical 
clustering. As shown in Figure 11, the DeCyder analysis data from 
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both DIGE experiments (cytosol and nucleus) divide along two main 
branches, with each dividing further into two branches, showing 
evidence of four major categories: two up-regulated categories in the 
upper dendrogram, and two down-regulated categories in the lower 
dendrogram. I observed that in the two cellular compartments there 
are two sub-clusters denoting proteins highly expressed at the 8 h and 
then lower expressed at 48 h, and proteins that are lower expressed at 
8 h and then highly expressed at 48 h.  
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Figure 11. Hierarchical clustering analysis. Hierarchical clustering analysis of 
protein-spots expression profiles in the cytosol (A) and nucleus (B) of the Lan5 cell 
line following 8, 24 and 48 hs of RA treatment (by column, as indicated). The up-
regulated proteins are in red, the down-regulated proteins are in green. The 
expression profiles of the identified protein spots, indicated by asterisks, are shown 
on the right side of the Figure. 
 
2. Mass Spectrometry 
 
To identify the differentially expressed proteins, 38 spots of interest 
were excised from the preparative gels, and in-gel trypsin digestion 
and mass spectrometry (MS/MS) analysis were performed for protein 
identification. Successful identification was achieved if at least five 
peptides of experimental MS/MS data matched the internal sequence 
of the theoretical candidate protein. Mass spectrometric analysis 
identified 33 proteins corresponding to 17 protein spots from the 
cytosolic fraction, and 16 from the nuclear fraction. The results of the 
protein identification are given in Tables 2 and 3, and the positions of 
the differentially expressed spots picked in the 2D gel are shown in 
Figure 12.  
In this study, I was not able to determine the identities of the protein 
components of other differentially expressed spots using either the 
MALDI-TOF or LC-MS/MS mass spectrometric techniques. This 
may in part be due to insufficient amounts of protein in the spots, and 
also to the scarcity of tryptic digestion sites. In several cases, some 
well-separated spots of similar mass but different charge were 
identified as the same proteins. This may imply alternative post-
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translational modifications, such as phosphorylation or multiple 
expression forms. 
 
Figure 12. The differentially expressed protein spots upon ATRA treatment. 
The differentially expressed protein spots upon ATRA treatment for cytosolic (A; 58) 
and nuclear fractions (B; 68). The arrows show the picked-up spots on the 
preparative gels and then identified: 17 spots for the cytosolic fraction and 16 spots 
for the nuclear fraction.  
 
These possibilities have not been studied further to date. Similarly, 
some different proteins co-migrated in the same spot under our 
experimental conditions, and the identified pituitary tumor-
transforming gene protein-binding factor PTTG1IP was detected in a 
spot which differed from its theoretical molecular mass and pI. This 
could reflect proteolytic degradation of the protein or post-
translational modifications, such as glycosylation. 
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Master 
Number Protein Name ID NCBI
ID 
SPROT
Theor. MW 
(kDa)
ExperimMW 
(kDa)§
Theor
pI
Experim
pI §
MS 
score
MS 
match
Fold 
48H/0H P value
800* Glucosamine--fructose-6-phosphate aminotransferase 1 gi/183082 Q06210 77,5 _ 6,39 _ 166 10 -1,34 0,00014
1876 Aspartate aminotransferase, cytoplasmic gi/105387 P17174 46,35 _ 6,81 _ 188 14 -1,87 0,03
1607* Tumor susceptibility gene 101 gi/60655269 Q99816 44,1 _ 6,06 _ 276 12 -1,52 0,023
1598 Enolase 1 Variant gi/62896593 P06733 47,5 _ 7,01 _ 125 12 -1,6 0,03
3098 dUTP pyrophosphatase gi/181844 P33316 15,5 _ 6,13 _ 126 8 -1,52 0,036
686 DEAD box protein 1, DDX1 protein gi/33877837 Q92499 78,8 _ 8,27 _ 151 17 -1,52 0,046
920 Heterogeneous nuclear ribonucleoprotein M gi/187281 P52272 77,9 _ 8,99 _ 115 16 -1,78 0,021
2705 Prefoldin subunit 3 gi/48429043 P61758 18,5 _ 6,63 _ 94 8 -1,73 0,0097
1607* Proliferation-associated protein 2G4 gi/5453842 Q9UQ80 44,2 _ 6,13 _ 261 13 -1,52 0,023
2856 Peroxiredoxin-2 gi/1617118 P32119 18,5 _ 5,19 _ 109 8 1,51 0,078
2107 L-lactate dehydrogenase B chain gi/49259212 P07195 36,8 _ 5,86 _ 184 14 -1,39 0,035
591 88,4 7,37 -1,56 0,014
593 88,3 7,52 -1,53 0,0036
578 88,8 7,65 -1,55 0,00017
1621 50,3 6,65 -1,73 0,018
1614 50,4 6,95 -1,69 0,022
1606* Elongation factor 1, alpha 1 gi/48734733 P68104 50,5 _ 9,14 _ 241 18 -1,69 0,031
921 acetyl-CoA carboxylase beta gi/1399290 O00763 89,8 _ 6,01 _ 80 14 -1,55 0,037
1607* 26S proteasome non-ATPase regulatory subunit 11 gi/2150046 O00231 47,7 _ 6,08 _ 318 20 -1,52 0,023
1621 Pituitary tumor-transforming gene protein-binding factor gi/21411022 P53801 21,2 _ 9,14 _ 202 5 -1,73 0,018
Catalytic activity (Ligase activity)
Molecular function unknown
Catalytic activity (Transaminase activity)
Nucleic acid binding (DNA binding)
Magnesium ion binding
Nucleic acid binding (RNA binding)
P13639 96,3 6,41
Protein binding
Catalytic activity (Hydrolase activity)
Catalytic activity (Oxidoreductase activity)
Translation  elongation factor activity
Human Elongation Factor 2 94 11
Elongation factor 1-gamma gi/15530265 P26641 50,5 6,25 202 12
gi/31108
Table 2. Proteins identified in the cytosolic fraction
 
 
Master 
Number Protein Name ID NCBI
ID 
SPROT
Theor. MW 
(kDa)
Experim 
MW(kDa)§
Theor
pI
Experim
pI§ 
MS 
score
MS 
match
Fold 
48H/0H P value
1895 45,7 5,04 -1,27 0,0037
1888 45,8 5,12 -1,35 0,014
1891 45,7 5,17 -1,44 0,0000072
1891 Eukaryotic initiation factor 4A-I gi/77735407 P60842 46 _ 5,38 _ 186 7 -1,44 0,0000072
1895 Eukaryotic initiation factor 4A-II gi/16198386 Q14240 46,6 _ 5,38 _ 256 11 -1,27 0,0037
1343* 58,3 6,52 1,68 0,02
1302* 58,8 6,68 1,59 0,00029
1353* 58,5 6,87 1,87 0,0055
1344* 58,6 7,06 1,65 0,00035
1232 68 kDa neurofilament protein gi/24658018 P07196 61,6 _ 4,64 _ 111 8 2,12 0,0018
1201 62,1 6,43 -1,29 0,013
1221 62 6,7 -1,26 0,0099
2508 Proliferating cell nuclear antigen gi/2914387 P12004 29,1 _ 4,57 _ 115 8 -1,75 0,003
1343* lamin A/C gi/55957499 P02545 69,5 _ 6,4 _ 386 7 1,68 0,02
1561 Dihydrolipoyl dehydrogenase, mitochondrial gi/71042410 P09622 50,7 _ 6,35 _ 86 7 -1,38 0,037
1664 Histone-binding protein RBBP4 gi/30583457 Q09028 47,95 _ 4,74 _ 149 10 -1,38 0,0037
1008 SecretograninII, Chromogranin C gi/134464 P13521 70,85 _ 4,67 _ 83 8 3,13 0,00032
2473 Guanine nucleotide-binding protein beta subunit 2 gi/20357529 P62879 38,1 _ 5,6 _ 148 11 1,44 0,01
2090 Stomatin (EPB72)- like 2 gi/14603403 Q9UJZ1 38,65 _ 6,88 _ 125 11 -1,21 0,054
1585 Disulfide isomerase ER-60 gi/860986 P30101 57,1 _ 6,1 _ 118 13 1,23 0,0027
1353* 58,5 6,87 1,87 0,0055
1302* 58,8 6,68 1,59 0,00029
1344* 58,6 7,06 1,65 0,00035
2681 brain and muscle Ah receptor nuclear translocator-like protein gi/7512308 31,6 _ 9,42 _ 94 7 2,14 0,041
8,88 600 10Very long chain acyl CoA dehydrogenase gi/3273228 P49748 70,85
Metal ion binding 
Signal transducer activity
Catalytic activity (Hydrolase activity)
Catalytic activity (Oxidoreductase)
13
Structural molecule activity
Nucleotide binding 
Protein binding
Q96AE4 67,65 7,18 178
Structural constituent of of cytoskeleton 
Nucleic acid binding (DNA binding)
FUSE-binding protein 1 gi/37078490
9
Heterogeneous nuclear ribonucleoprotein Q gi/21619168 O60506 58,95 7,18 325 7
P52597 46
Table 3. Proteins identified in the nuclear fraction
Nucleic acid binding (RNA binding)
Heterogeneous nuclear ribonucleoprotein F gi/76780063 5,38 103
 
The asterisk (*) indicates the spots that were identified by LC-MS/MS analysis. 
(§) Experimental MW and pI, calculated by DeCyder 5.0 software are reported only for proteins 
identified in more than one spot, in order to assess post-translational modifications. 
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3. Gene Ontology  
 
I performed functional classification of the proteins identified 
according to the DAVID 2.1 beta annotation system. Statistical 
analysis (Fisher exact test) of the 17 cytosolic proteins identified 
(Figure 13A) indicated that some functional categories are 
overrepresented in this list, such as translation elongation factor 
activity, catalytic activity, transaminase activity, transferase activity, 
and the transferring of nitrogenous groups. Moreover, the functional 
category RNA binding was overrepresented in the list of the 16 
nuclear proteins identified (Figure 13B).  
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Figure 13. Gene ontology. The proteins identified were classified using the DAVID 
2.1 beta annotation system. The Fisher exact test was used to determine the protein-
enrichment in annotation terms. The functional categories are sorted by P value. 
Statistical analyses (Fisher exact test) of the cytosol proteins (A) and the nuclear 
proteins (B) are shown. The graphic shows the number of proteins within each 
functional category. 
 
 
 
 
 
 68
4. Gene Mapping 
To examine the correlations between the proteins showing RA-
induced differential expression and the chromosomal rearrangements 
or epigenetic regulatory loci in NB, I searched for the physical 
location of the genes coding for the differentially expressed proteins, 
using UNIGENE searching of the NCBI genome database. This 
revealed that the DLD (dihydrolipoamide dehydrogenase), ENO1 
(enolase variant 1), DDX1 (ATPdependent RNA helicase), ACACB 
(acetyl-CoA carboxylase beta), PSMD11 (26S proteasome non-
ATPase regulatory subunit 11) genes map to allelic imbalance 
chromosomal regions involved in NB (Table 4).  
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Table 4 Mapped Chromosomal regions of genes coding for the identified 
proteins. 
Protein name Gene Name
Mapped 
chromosomal 
regions
Glucosamine--fructose-6-phosphate aminotransferase 1 GFPT1 2p13
Aspartate aminotransferase, cytoplasmic GOT1 10q24.1-q25.1
Tumor susceptibility gene 101 TSG101 11p15
Enolase 1 Variant ENO1 1p36.3-p36.2 *
dUTP pyrophosphatase DUT 15q15-q21.1
DEAD box protein 1, DDX1 protein DDX1 2p24 *
Heterogeneous nuclear ribonucleoprotein M HNRPM 19p13.3-p13.2
Prefoldin subunit 3 VBP1 Xq28
Proliferation-associated protein 2G4 PA2G4 12q13
Peroxiredoxin-2 PRDX2 19p13.2
L-lactate dehydrogenase B chain LDHB 12p12.2-p12.1
Human Elongation Factor 2 EEF2 19pter-q12
Elongation Factor 1-gamma EEF1G 11q12.3
Elongation Factor 1, alpha 1 EEF1A1 6q14.1
acetyl-CoA carboxylase beta ACACB 12q24.11 *
26S proteasome non-ATPase regulatory subunit 11 PSMD11 17q11.2 *
Pituitary tumor-transforming gene protein-binding factor PTTG1IP 21q22.3
Heterogeneous nuclear ribonucleoprotein F HNRPF 10q11.21-q11.22
Eukaryotic initiation factor 4A-I EIF4A1 17p13
Eukaryotic initiation factor 4A-II EIF4A2 3q28
Heterogeneous nuclear ribonucleoprotein Q SYNCRIP 6q14-q15
68 kDa neurofilament protein NEFL 8p21
FUSE-binding protein 1 FUBP1 1p31.1
Proliferating cell nuclear antigen PCNA 20pter-p12
lamin A/C LMNA 1q21.2-q21.3
Dihydrolipoyl dehydrogenase, mitochondrial DLD 7q31-q32 *
Histone-binding protein RBBP4 RBBP4 1p35.1
SecretograninII, Chromogranin C SCG2 2q35-q36
Guanine nucleotide-binding protein beta subunit 2 GNB2 7q21.3-q22.1
Stomatin (EPB72)- like 2 STOML2 9p13,1
Disulfide isomerase ER-60 PDIA3 15q15
Very long chain acyl CoA dehydrogenase ACADVL 17p13-p11
brain and muscle Ah receptor nuclear translocator-like protein § §
Table 5. Mapped chromosomal regions of genes coding for the identified proteins
 
*Genes coding for the identified proteins that are mapped to regions known to be altered in NB. 
 
5. Validation and Analysis in Different Human NB Cell 
Lines. 
I performed validation of the data for some of the identified proteins 
based on the availability of good commercial antibody by Western 
blotting: PRX II (peroxyredoxin-2), SgII (secretogranin II), NEF-L 
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(68kDa neurofilament), eEF-1R (eukaryotic elongation factor), PCNA 
(proliferating cell nuclear antigen), EF-2 (elongation factor-2), 
prefoldin subunit 3 and Gβ2 (guanine nucleotide-binding protein beta 
subunit 2) (Figure 14A). I performed semi-quantitative analysis of the 
protein expression on total amount of proteins at the four time points 
of the differentiation: 0, 8, 24, and 48h. The bands were quantified by 
densitometry to obtain an integral optic density (IOD) value which 
then was normalized with respect to β-actin value (Figure 14B). 
 
Figure 14. Western blot analysis of selected proteins in LAN-5 cells. Western 
blot analysis of selected proteins was performed in LAN-5 cells, not treated or 
treated with 5 µM RA for 8, 24 and 48hs. The β-actin was used as the loading 
control (A). The bands were quantized by densitometry. The bar graph shows 
integral optic density (IOD) value for each band, normalized with respect to β-actin 
expression (B). 
 
 All of these proteins showed differential expression patterns in the 
LAN-5 cell line, according to the DIGE results. I also analyzed the 
expression patterns of these selected proteins in two other NB cell 
lines, SH-SY5Y and SK-N-BE, not treated and treated with RA for 
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48h (Figure 15A). Here, the proteins TSA, SgII, NF-L, EF1R, PCNA, 
and EF-2 showed the same trends seen in the LAN-5 cells, while the 
prefoldin 3 and Gβ2 proteins were differentially expressed in the SH-
SY5Y cells, and not in the SK-N-BE cells. Semi-quantitative analysis 
of the protein expression at the two extreme time points of 
differentiation: 0 and 48 h, in LAN-5, SH-SY-5Y, and SK-N-BE cells 
was shown in Figure 15B.  
 
Figure 15. Western blot analysis of selected proteins was performed in LAN-5, 
SH-SY5Y and SK-N-BE cells. Western blot analysis of selected proteins was 
performed in LAN-5, SH-SY5Y and SK-N-BE cells, with (+) and without (-) N-MYC 
amplification, either not treated or treated with 5 µM RA for 48hs. The β-actin was 
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used as the loading control (A). The bar graph shows the IOD as fold of induction 
expressed at 48hs of RA differentiation. Proteins expression level at 0h was assigned 
equal to 100% (B). The arrows show two proteins which were found differentially 
expressed in LAN-5 and SH-SY5Y cells and not differentially expressed in SK-N-BE 
cells. 
 
I also checked the variation of expression of prefoldin 3 and DDX1 
proteins in the cytosol and nuclear fraction separately, upon ATRA 
treatment at 48h. As observed in Figure 16, prefoldin 3 expression 
decreases in cytosol and does not change in nucleus fraction, whereas 
DDX1 expression increases in nucleus and decreases in cytosol 
fraction. 
 
C 
 
Figure 16. Prefoldin 3 and DDX1 ATRA differentially expression. Prefoldin 3 
DIGE differentially expression in cytosolic fraction was output by Biological 
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Variation Analysis (BVA). Each point represents the standardized log abundance 
(sample/internal standard) of a protein spot obtained for each of the 12 gels 
analysed: 3 gels loaded proteins at 0h, 3 gels loaded proteins at 8hs RA, 3 gels 
loaded proteins at 24hs RA and 3 gels loaded proteins at 48hs RA. A paired 
Student’s t-test was applied to all samples, yielding a p-value 0.0097 and fold 
48h/0h -1.73 (A). Western blotting of prefoldin 3 (B) and DDX1 (C) was performed 
on LAN-5 nuclear and cytosol fractions, not treated or treated with 5 µM RA for 
48hs. The β-actin and lamin β were used as the loading control. In (C) the bands 
were quantized by densitometry. IOD value was normalized respect to b-actin 
expression values. 
 
6. VBP1 survival correlation in primary NB  
Gene coding Prefoldin 3 is called VBP-1, as Von Hippel-Lindau 
binding protein 1. I analysed the correlation of  VBP-1 mRNA 
expression to survival in a cohort of 102 primary NBs (Affymetrix 
U133v2 chips). The macroarray experiment was already performed 
(Schulte et al., 2005; Schramm et al., 2005b). I found a statistically 
significant correlation of VBP-1 high espression to bad survival. (p-
value 0,00048 ) (Figure 17). 
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Figure 17 VBP1 (Von Hippel-Lindau binding protein 1)  expression survival in 
NB. The survival curve of 102 patients with NB shows a significant association of 
high expression of VBP-1 to patients that have less month of follow up. The value of 
expression of VBP-1 was analysed by a software. 
 
7. Gal-1 mRNA expression correlates with neurotrophin 
receptor expression in primary NB 
I analysed the correlation between Gal- 1 and Trk receptors mRNA 
expression in a cohort of 102 primary NBs (Affymetrix U133v2 
chips). Gal-1 expression correlated significantly with the levels of 
TrkB expression (P=4x10-9) and was anticorrelated with TrkA 
expression (P=6x10_3, Figure 18).  
 
 
Figure 18 Correlation of Gal-1 and Trk expression in primary NB. Gal-
1/LGALLS1 expression was significantly correlated with TrkB/NTRK2 expression 
(P=4x10-9) and significantly anticorrelated with TrkA/NTRK1 (P=0,006) in a cohort 
of 102 primary NB. 
 
In addition, in our model system SY5Y, Gal-1 protein and mRNA 
levels increased on activation of TrkB by BDNF in SY5Y-TrkB, but 
not on activation of TrkA by nerve growth factor (NGF) in SY5Y-
TrkA or in the vector control SY5Y-vec (Figure 19a, 19b). 
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B 
 
Figure 19. Gal-1 expression in SY5Y cells. Gal-1 expression was evaluated by 
western blotting (A). and RT-PCR (B). Gal-1 levels significantly increased (P0 
0,015, t-test) on stimulation of SY5Y-TrkB with BDNF. No significant changes in 
Gal-1 were observed in SY5Y-TrkA or in control-transfected cells (SY5Y-vec) 
following neurothrophin treatment. 
 
Furthermore, recombinant Gal-1 (rGal-1) induced Gal-1 mRNA 
expression only in SY5Y-TrkB, but not in SY5Y-TrkA cells, 
suggesting a feedback activation loop (Figure 20a). Interestingly, this 
effect could be reverted if the sugar-binding capacity of Gal-1 was 
blocked by the addition of lactose, whereas cell proliferation was not 
A 
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affected by rGal-1 (Figure 20b). Taken together, Gal-1 expression was 
found to be tightly linked to TrkB expression in vivo and in vitro. 
 
Figure 20. rGal-1 mediated effects. Addition of r-Gal-1 to medium of TrkB-
expressing cells significantly (P=0,05, t-test) increases expression of Gal-1, which 
can be inhibited by competition with lactose(A), although not significantly altering 
cell proliferation measured by MTT assay. rGal-1 does not affect Gal-1 expression 
in SY5Y-TrkA or control cells (SY5Y-vec) (B). 
 
8. Gal-1 protein is highly expressed in primary NB 
To analyse Gal-1 expression in situ, I hybridized a tissue microarray 
containing 92 primary NBs with a Gal-1-specific antibody. There 
were distinguishable patterns of Gal-1-staining intensity in the tumor 
cells (Figure 21) with a trend toward elevated expression in higher 
tumor stages, but statistical analyses revealed no significant 
correlation between Gal-1 protein expression and patient survival or 
clinical parameters, including age at diagnosis, stage or MYCN 
 
A 
B 
 77
amplification (data in text only). Interestingly, Gal-1 expression was 
also high in stromal septae, in particular, in differentiating tumors. 
 
Figure 21. Immunohistochemical staining of Gal-1 in primary NB. Three 
rappresentative examples of a total 92 NB tumors analysed are shown. The left and 
the middle pictures show sections from INSS stage 4 NB, poorly differentiated; left: 
MYCN-amplified tumor with 1p del; middle: MYCN single copy with normal 1p. the 
pictures on the right is derived from an INSS stage 1, differentiating NB with single 
copy MYCN. Note the extracellular and cytoplasmic staining of Gal-1, as well as the 
positively stained septae (marked by arrows in the right picture). 
 
9 Gal-1 contributes to BDNF-mediated invasion of 
SY5Y-TrkB cells 
The invasive capacity of SY5Y-TrkA and SY5Y –TrkB cells was 
assessed using a Boyden chamber assay. Although neurotrophin 
receptor activation resulted in very few migrating cells in SY5Y-TrkA 
and empty vector control, migration of SY5Y-TrkB cells was strongly 
enhanced on TrkB activation by BDNF (Figure 22).  
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Figure 22.Invasion mediated by TrkB stimulation. Stimulation of TrkB receptor 
by BDNF is required for the invasion of SY5Y-TrkB cells, whereas NGF treatment of 
SY5Y-TrkA or neurotrophin treatment of control cells (SY5Y-vec) has only a minor 
effects on the invasive capacity properties. 
 
The addition of rGal-1 alone modestly enhanced the migratory 
capacity of TrkB cells, whereas blocking Gal-1 function using a 
neutralizing anti-Gal-1 antibody strongly reduced BDNF-mediated 
migration of SY5Y-TrkB cells. (Figure 23). rGal-1 and BDNF 
cooperatively induced cell migration in SY5Y-TrkB (Figure 23b, 
lower right part). I also aimed to assess whether the intracellular or 
extracellular function of Gal-1 is required for invasion. For this 
purpose, I knocked down the intracellular pools of Gal-1 by siRNA 
and added rGal-1 simultaneously. The down regulation of Gal-1 by 
siRNA strongly reduced the invasiveness of BDNF-activated TrkB-
expressing cells, which could be restored by the addition of rGal-1 
(Figure 24). In summary, this suggests a strong impact of extracellular 
Gal-1 on the invasive capacity of TrkB-expressing NB cells. 
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Figure 23 Gal-1 contributes to BDNF-mediated invasion.. A neutralizing antibody 
directed against Gal-1 reduces the invasive capacity of BDNF-stimulated SY5Y-
TrkB cells. Addition of rGal-1 to the medium of unstimulated SY5Y-TrkB cells 
increases the number of invading cells but it is not sufficient to restore  fully the 
invasive capacity of SY5Y-TrkB cells in presence of BDNF. 
 
 
Figure 24. Extracellular Gal-1 effect on TrkB mediated.invasion. Inhibition of 
BDNF-triggered invasion mediated by a siRNA directed against Gal-1 can be 
overcome by addition of recombinant Gal-1 (rGal-1; CTR= control using an 
unrelated siRNA sequence, NTC= control using transfection reagent only). Only 
when intracellular Gal-1 levels were depleted by a Gal-1 specific siRNA, addition of 
rGal-1 significantly increased the number of invading cells (p= 0.03, t-test).  
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9.1 Gal-1 silencing by siRNA 
I used three different siRNA directed against Gal-1 mRNA. The 
efficiency of silencing was checked by RT-PCR and Western Blotting 
as shown in Figure 25. The mostly effective siRNA were siRNA3 and 
siRNA7 which were used for the described experiments. 
 
 
Figure 25. Gal-1 expression silencing. Gal-1 expression was silenced by using 
separatly three different siRNA against three different regions on Gal-1 transcript. 
The knockdown efficacy was checked by RT-PCR (A) and by Western Blotting(B). A 
non-targeting siRNA- control (NTC) and buffer transfected control (0-CTR) were 
used to assure the target specificity. 
 
10. Downregulation of Gal-1 abrogates migration of 
SY5Y-TrkB cells 
Next, I analysed the migration capacity of Trk-expressing SY5Y cells 
in a ‘wound-healing’ assay. After scratching, SY5Y-TrkA or SY5Y-
TrkB was incubated in the presence or absence of neurotrophins. 
BDNF treatment of SY5Y-TrkB cells enhanced migration, which was 
impaired by transient siRNA-mediated silencing of Gal-1, but not by a 
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control siRNA (Figure 26a). SY5Y-TrkA cells as well as SY5Y empty 
vector cells did not migrate irrespective of neurotrophin treatment 
(Figure 26b). These experiments show that Gal-1 expression is an 
essential parameter for the migration capacity of SY5Y-TrkB cells. 
BDNF-mediated up-regulation of Gal-1 expression strictly depends on 
TrkB receptor activation.  
 
Figure 26. Gal-1 effect on TrkB mediated.migration (A) BDNF treatment of 
SY5Y-TrkB cells enhances migration within 2 days following scratching. This is 
impared by si-RNA-mediated  silencing of Gal-1 compared with untreated control or 
unrelated si-RNA. (B) NGF treatment of SY5Y-TrkA cells does not enhance 
migration and neither does NT treatment of control cells (SY5Y-vec). 
 
11. Gal-1 is strictly dependent on TrkB pathway 
The contribution of an activated and functional TrkB signaling 
pathway to the regulation of Gal-1 expression was assessed using 
K252a, a general inhibitor of Trk signaling. The activation of TrkB by 
BDNF induced an increased phosphorylation of Akt (p-Akt) in 
SY5YTrkB cells that was inhibited by K252a (Figure 27). Akt 
activation could be restored only partially by the simultaneous 
addition of BDNF and K252a. I did not find Akt activation in control-
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transfected cells (SY5Y-vec) on neurotrophin addition, but only an 
increase in p-Akt on treatment with K252a. BDNF mediated up-
regulation of Gal-1 expression in SY5YTrkB was abrogated when the 
TrkB receptor was inhibited by K252a alone or by the simultaneous 
addition of BDNF and K252a (Figure 27). These findings strongly 
suggest that Gal-1 up-regulation is strictly dependent on a functional 
TrkB pathway. 
 
Figure 27. Gal-1 is strictly dependent on TrkB pathway activation BDNF-
mediated activation of TrkB induces an increased p-Akt in SY5Y-TrkB cells that is 
inhibited by TrkB  inhibitor K252a. No activation of Akt can be seen in control cells 
(SY5Y-vec) without TrkB  expression following neutothrophin (NTs= simultaneous 
addition of BDNF+NGF) treatment. Expression of Gal-1 is reduced when TrkB 
signalling is inhibited bt K252a or by simultaneous addition of BDNF and K252a in 
SY5Y-TrkB cells, but nit in the controls (SY5Y-vec). 
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Discussion 
 
 
NB is an heterogeneous tumor which shows a wide range of genetic 
alterations and biological phenotypes. Even if there are so many 
altered pathways and so many biological markers known to be 
involved in molecular mechanism of this tumor, to date there isn’t 
been defined a common mechanism of insurgence and progression.   
Standard therapy for patients who have low- and intermediate-risk NB 
involves tumor primary resection and moderate-dose chemotherapy 
including cisplatin, doxorubicin, etoposide, and cyclophosphamide. 
Standard therapy for patients who have high-risk NB involves 
chemotherapy in escalated dose intensity (anthraciclines, alkylators, 
platinum compounds, and topoisomerase II inhibitors), surgical 
resection and radiotherapy to the primary tumor. Minimal residual NB 
are treated by isotretinoin (cis-RA) or monoclonal antibodies directed 
against gangliosidase GD2.  
The knowledge of NB biology is imperative toward the use of novel 
therapies for high-risk NB. Several biologic agents are in ongoing 
clinical trials for recurrent NB, including histone deacetylase 
inhibitors, Trk tyrosine kinase inhibitors, and anti-angiogenic agents. 
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These agents will be moved into-front line therapy to optimize 
treatment of  minimal residual disease. 
The goal of this thesis has been the discovery of novel therapeutic 
targets in NB therapy, using the mounting knowledge of NB tumor 
biology as the differentiation/regression ability and the well-
characterized TrkA and TrkB pathways whose mediators are 
responsible of two biological phenotypes. 
In the first part, I applied a systematic approach as proteomics to get 
deeper in the molecular mechanism of ATRA-induced differentiation 
in NB cells in order to clarify pathways and molecular targets most 
drivers of NB differentiation. In the second part, I focused on the 
functional study of Gal-1 which is a down-stream mediator of TrkB 
pathway, whose expression is mostly associated with high-risk group 
patients. Although Trk inhibitors are actually used in clinical trials, 
specific targeting TrkB pathway by means of Gal-1 silencing should 
be a novel therapeutic strategy to be suggested in the current 
protocols.  
 
1.First Aim: 
Comparative proteomic expression profile in All-trans 
Retinoic Acid differentiated NB cell line. 
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NB shows the highest rate of spontaneous regression of any human 
tumour, mainly due to differentiation and maturation of these highly 
malignant cells in neurons. It is of interest to study the molecular 
pathways driving spontaneous regression in NB in order to unravel the 
molecular basis of NB development and the driver-pathways and 
markers to be suggested as targets in differentiation therapy.  
ATRA, the most commonly used anti-neoplastic agent in NB therapy, 
can induce neural differentiation in NB cell lines in vitro (Sidell et al., 
1982). Systematic approaches at the transcription and translational 
levels have been used to identify the target genes for NB progression. 
Moreover, studies of differentiation induced by ATRA have been 
performed in PML cells and in mouse stem cells using a proteomic 
approach. 
The main aim of our study was to gather insights into the molecular 
mechanisms of NB differentiation using 2-D DIGE technology. I used 
the human LAN-5 NB cell line amplified for the oncogene N-MYC 
and responsive to ATRA treatment (Cesi et al., 2002; Hettmer et al., 
2004), and monitored the cytosolic and nuclear protein expression in 
those cells at the early phase of ATRA differentiation. I used 5 µM 
ATRA, according to the known pharmacological doses used in phase I 
trials of RA administrated to NB patients (Villablanca et al., 1995).  
I detected a total of 58 spots in the cytosolic fraction and 68 in the 
nuclear fraction that showed differences in their relative expression 
between the control and RA-treated LAN-5 cells; 33 of these proteins 
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were identified (17 in the cytosolic fraction and 16 in the nuclear 
fraction). In agreement with the neuronal-orientated differentiation 
induced by ATRA, I observed at early phase of differentiation a 
substantial up-regulation of the NEF-L and SgII proteins, which are 
known to be neuronal markers (Pagani et al., 1992; Giudici et al., 
1992; Jang et al., 2004), and the down-regulation of the proliferating 
cell nuclear antigen PCNA, an auxiliary protein of DNA polymerase. 
The highest levels of PCNA were seen in advanced NB stage tumours 
with an amplified N-myc gene (Keim et al., 1993; Mejia et al., 2003). 
Our results suggest that the decreased levels of PCNA may reflect 
differences in proliferative activity and that the suppression of 
proliferation is an obligatory step in the differentiation of these cancer 
cells. Far upstream element Binding Protein 1 (FBP) stimulates the 
expression of c-myc, a transcription factor involved in cell growth, 
proliferation, differentiation and apoptosis (Ducan et al., 1994). FBP 
down-regulation upon ATRA differentiation was observed in our 
model systems as well has also been seen in differentiated 
haematopoietic stem cells (Tao et al., 2004). 
Closed examination of the list of differentially expressed identified 
proteins shows that those of greatest relevance are annotated to the 
“translational elongation factor activity” and “RNA-binding” 
functional categories. Most of the proteins related to these categories 
were down-regulated during RA differentiation. Among these, the 
initiation factor IF-2, the elongation factors eEF-1gamma and eEF-
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1alpha1, the heterogeneous nuclear ribonucleoprotein hnRNP F, and 
the eukaryotic initiation factors eIF4A-1 and eIF4A-2 are known to be 
down-regulated by ATRA in acute promyelocytic cells (Harris et al., 
2004; Zheng et al., 2005; Guo et al., 2001). In particular, IF-2, eEF-
1gamma and eEF-1alpha1 have roles in the elongation stages of the 
protein synthesis mechanism, and hnRNP F, eIF4A-1 and eIF4A-2 
have roles in mRNA processing and transport. This may suggest that 
ATRA-induced differentiation of NB could share these six effectors 
with ATRA-induced differentiation in PML cells.   
A group of enzymes involved in biochemical metabolism was found 
to be significantly down-regulated, implicating the suppression of 
related biochemical pathways in ATRA-treated cells (dihydrolipoyl 
dehydrogenase, glucosamine-fructose-6-phosphate aminotransferase 
1, aspartate aminotransferase, enolase variant 1, L-lactate 
dehydrogenase B chain, acetyl CoA carboxylase beta). The down-
regulation of lactate dehydrogenase (LDH) is also interesting, as it is a 
characteristic serum marker that is useful in facilitating diagnosis, 
prognosis and monitoring disease progression in children affected by 
NB.  
Several genomic alterations in NB have been reported to correlate 
with prognosis, including amplification of MYCN oncogene, gain of 
chromosome 17q and loss of chromosome 1p36. Other recurrent 
changes have also been suggested to have relevance to the 
development and progression of these tumours (Bown et al., 2001; 
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Maris et al., 1999). Our results show that some of the genes coding for 
the identified proteins mapped to chromosomal regions that are known 
to be altered in NB. Among these, the acetyl CoA carboxylase beta 
ACACB gene which is mapped to allelic imbalance NB region 
(17p13-p11) and the ENO1 gene into a loss chromosomal NB region 
(1p36.3-1p36.2). Moreover, enolase variant 1, which was down-
regulated in our system, has been seen to be up regulated in 
undifferentiated haematopoietic cells (Tao et al., 2004). The DLD, 
DDX1 and PSMD11 genes mapped to gain NB regions (Mosse et al., 
2005; Chen et al., 2004; Hackett et al., 2003). The dihydrolipoyl 
dehydrogenase DLD protein level, which is down-regulated in our 
model system, has been seen to increase in the central nervous system 
of rats after oxidative stress (Poon et al., 2006). The DDX1 gene 
coding for the DEAD box protein 1 which is down-regulated in our 
model system, has been shown to be over-expressed in a subset of 
unfavourable NBs and in retinoblastoma cell lines (Godbout et al., 
1998); it has been mapped to chromosome 2p24 and found often co-
amplified with the proto-oncogene MYCN in patients with a worse 
prognosis (Pandita et al., 1997; Manohar et al., 1995) than in patients 
with only the MYCN gene amplified (Squire et al., 1995; George et 
al., 1996). The role of DDX1 in the tumorigenic process is not known 
though; it is a putative RNA helicase, predicted to be involved in 
RNA binding and in the export of mRNA from the nucleus to the 
cytoplasm (Scott et al., 2003; Bleoo et al., 2001). It is both 
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cytoplasmatic and nuclear in DDX1-MYCN amplified NB and RB 
cell lines. However, it is known to localize specifically to the nucleus 
in non MYCN amplified cell lines. In LAN-5 cells, I observed a 
correlation between MYCN amplification and DDX1 nuclear 
translocation upon ATRA treatment. These findings may support the 
hypothesis of its putative RNA shuttle function into the nucleus as a 
sign of good prognosis upon ATRA differentiation. 
Other down-regulated proteins identified in our study have been 
associated to the aggressiveness of several tumours. This would 
suggest that the cells are regressing from their tumoral state, following 
RA treatment. Among these, there are pituitary tumour-transforming 
gene protein-binding factor PTTG1IP and ribonucleoprotein hnRNP 
F. PTTG1IP is a prognostic indicator in thyroid cancer, even if its 
precise contribution to tumorigenesis has not yet been explored 
(Stratford et al., 2005). Also, increased expression of hnRNP F has 
been seen in more aggressive colorectal tumours. This suggests 
hnRNP F as a potential marker for colorectal cancer progression 
(Balasubramani et al., 2006). Furthermore, the DDX1, eIF4A1, 
eIF4A2, eEF1-gamma and LDH genes are detected in several NB 
cDNA libraries. Moreover, eIF4A1 mRNA has been shown to be 
consistently over-expressed in human melanoma cells in vitro (Eberle 
et al., 1997), in hepatocellular carcinoma (Shuda et al., 2000; Yoon et 
al., 2006) and in early-stage non–small-cell lung cancer (Ji et al., 
2003). 
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The SH-SY5Y and SK-N-BE human NB cell lines are able to undergo 
neuronal differentiation in presence of ATRA. The SH-SY5Y cell line 
is not amplified (Biedler et al., 1973) and the SK-N-BE cell line is 
amplified for the oncogene MYCN (Biedler et al., 1976) an important 
determinant of RA response in vitro and patient prognosis in vivo 
(Bordow et al., 1998). Either has often been used as one of the models 
for the analysis of neuronal function and differentiation. According to 
it, I saw that the neural markers SgII and NEF-L and the proliferating 
marker PCNA, were differentially regulated by RA in the SH-SY5Y 
and SK-N-BE cell lines as compared to the LAN-5 cell line. In the 
three cell lines I also observed the PRDX2 protein up-regulation 
which has been seen in the SH-SY5Y cell line upon treatment with the 
anti-neoplastic drug ectoposide (Urbani et al., 2005) and during 
differentiation of embryonic stem cells to neural cells by ATRA (Guo 
et al., 2001). Moreover I observed that the ATRA treatment down-
regulates the EF1α and EF-2 proteins and this effect has just been 
reported in promyelocitic cells. 
After ATRA treatment, Gβ2 and prefoldin subunit 3 were 
differentially expressed in the SH-SY5Y cells as compared to the 
LAN-5 cells, although they were not differentially expressed in the 
SK-N-BE cell line. Here I assay three independent cell lines: two N-
MYC duplicated and one without amplification. Indeed the three cell 
lines have different tumoral origins and the un-regulation of these two 
proteins in SK-N-BE cells might suggest that NB ATRA-induced 
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differentiation may involve different pathways. Gβ2 is an important 
regulator of certain signal-transduction receptors and effectors and is 
ubiquitously expressed in human tissues. Nothing of this protein was 
known to be associated with the tumour process or to be regulated by 
RA. Prefoldin subunit 3/vbp1 protein is a chaperone that captures 
proteins in unfolded state and transfers them to cytosolic chaperonin 
for functional folding. To our knowledge, the role of prefoldin 
proteins is not known in differentiation per se or in neural 
differentiation. I saw that it decreased in cytosolic fraction upon RA 
treatment. Thought proteomic approach it was found that proteins 
containing prefoldin structures increased during neural differentiation 
(Oh et al., 2006). Additionally, it was shown that the chaperonin 
prefoldin 3 binds the Von Hippel-Lindau (VHL) tumor suppressor 
gene product (Woodward et al., 2000; Brinke et al., 1997). VHL is 
involved in the ubiquitination and subsequent proteasomal 
degradation via the VHL ubiquitination complex (Iwai et al., 1999; 
Lisztwan et al., 1999) and in the down-regulation of transcriptional 
elongation (Maxwell et al., 1999). Because prefoldin 3 functions as a 
chaperone protein, it may play a role in the transport of the Von 
Hippel-Lindau protein from the perinuclear granules into the 
cytoplasm for the ubiquitination of hypoxia-inducible factor, an 
important step in the development of angiogenic tumours. VHL 
alteration gene leads to VHL disease which is associated with various 
rare neoplasias, including haemangioblastoma of the central nervous 
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system, retinal angioma, clear cell renal carcinoma and 
pheochromocytoma (Gnarra et al., 1996) (OMIM 193300). VHL gene 
is mapped on chromosome 3p25 and the loss of this region is a non-
random alteration associated to aggressive NBs (Spits et al., 2003). 
Furthermore, its mRNA expression level is a promising marker to 
predict patient survival in NB (Hoebeeck et al., 2006). It is known the 
inhibition of endogenous expression of VHL protein in SHSY5Y cells 
reduced neuronal properties. In conclusion VHL protein has a 
neuronal differentiating potential to transform NB cells into functional 
neuron-like cells (Murata et al., 2002; Kanno et al., 2000). To date, 
the role of prefoldin 3 in NB has not been investigated. It is known to 
have a cytoplasmatic location, but in presence of VHL protein has a 
nuclear location (Tsuchiya et al., 1996). As shown in Figure 16, 
prefoldin 3 has a preferential location in the nuclear compartment 
upon ATRA differentiation while in the cytoplasm is observed a 
decreased expression. This data underline the potential new role of 
prefoldin 3 in the nuclear compartment during differentiation process.  
Gene coding prefoldin 3 is VBP-1 (Von Hippel-Lindau binding 
protein 1). I also checked the correlation of VBP-1 expression in a 
cohort of 102 primary NB to survival, founding that high expression 
of VBP-1 is significantly correlated to bad survival. This observation 
and the previously shown VBP-1 down regulation in NB cells 
following ATRA-induced differentiation, lead to suggest VBP-1 as an 
important marker in the treatment of minimal residual disease. 
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Moreover the speculation on the role of prefoldin 3 together with 
VHL protein in the progression of NB might be an important issue for 
the future studies on NB tumor. 
 
2. Second Aim:  
Galectin-1 is a major effector of aggressiveness in TrkB-
expressing NB 
 
Another aspect of  NB is the treatment of more aggressive forms 
which are resistant to chemotherapy. To minimize the presence of 
minimal disease residues, it is necessary to develop a therapeutic 
strategy hitting the aggressive tumors in a multistep way. 
Aggressiveness defined by tissue invasion and metastasis is a 
hallmark of cancer cells (Hanahan and Weinberg, 2000). In NB, 
several factors have been identified to be associated with aggressive 
tumor behaviour, including deletion or epigenetic silencing of 
caspase-8 (Eggert et al., 2001; Teitz et al., 2000), expression of the 
HGF/c-met axis (Hecht et al., 2004; Hecht et al., 2005) as well as 
expression of full-length TrkB and its cognate ligand BDNF 
(Matsumoto et al., 1995). The latter is also associated with 
amplification of the MYCN oncogene, which is the strongest 
independent marker of outcome in NB (Nakagawara et al., 1994). On 
the other hand, expression of the neurotrophin receptors TrkA 
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(Nakagawara et al., 1993) and TrkC (Yamashiro et al., 1997) are 
found in favourable NBs, with high expression of TrkA been 
accompanied by massive changes in the transcriptome of NB 
(Schramm et al., 2005b). This biological diversity between TrkA and 
TrkB expression could also by verified in vitro (Lucarelli et al., 1997; 
Schramm et al., 2005a). Taken together, identification of effector 
targets differentially regulated between TrkA and TrkB expressing 
NBs could serve as drug targets for NB treatment. A cohort of 102 
primary NBs was screened for differentially expressed genes between 
TrkA and TrkB and compared the results to gene and protein lists 
obtained in a NB cell line model, SY5Y, with ectopic expression of 
either TrkA or TrkB (Schulte et al., 2005; Sitek et al., 2005). One of 
the most promising candidate genes identified in this analysis was 
Galectin-1 (GAL-1), which has been suggested as a cancer target 
before (Rabinovich, 2005; Salatino et al., 2008). I found a direct and 
significant correlation of mRNA expression of TrkB and Gal-1 in 
primary NB, while TrkA and Gal-1 expression were significantly anti-
correlated (Figure 10). This clearly stresses the importance of the in 
vitro findings and suggested a functional link between Trk expression 
and Gal-1 expression also in the primary tumors. This is important, 
because inhibition of Gal-1 functions by siRNA has been shown to 
inhibit tumor angiogenesis, which can be accomplished by siRNA 
(Mathieu et al., 2007) or a Gal-1 specific peptide (Thijssen et al., 
2006).  
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Gal-1 expression has also been correlated to tumor aggressiveness 
(Chiang et al., 2008; Jung et al., 2007). In invasive breast cancer, Gal-
1 was found in cancer-associated stromal cells (Jung et al., 2007), 
which is in accordance with our findings in NB (Figure 13). However, 
in contrast to the situation in breast cancer, I could not establish a link 
of stromal Gal-1 expression to NB progression. Nevertheless, the 
results prompted us to investigate the consequences of modulating 
Gal-1 functions in our model system.  
BDNF-mediated activation of TrkB increased Gal-1 expression on 
mRNA and protein levels in SY5Y-TrkB cells but not in 
neurotrophin-treated SY5Y-TrkA or control-transfected cells, in line 
with previous shown results in a proteomic study (Sitek et al., 2005). 
Therefore, I not only focused on the differences between TrkA- and 
TrkB-expressing cells but also analysed the consequences of 
neurotrophin treatment in our model systems. BDNF markedly 
increased the invasiveness of SY5Y-TrkB cells and this capacity was 
reduced by neutralising Gal-1 function (Figure 15). rGal-1 alone was 
not sufficient to induce the full invasive capacity of SY5Y-TrkB cells, 
suggesting that other BDNF-induced factors are involved in invasion 
as well. Previously, MCSP and c-Met have been suggested to be 
TrkB-regulated and to contribute to invasion in NB (Hecht et al., 
2005; Schulte et al., 2005). These current findings identify Gal-1 as a 
third player contributing to TrkB-mediated invasiveness in NB. 
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Since Gal-1 can exert its functions extracellularly as well as 
intracellularly I conducted a rescue experiment, in which the 
intracellular pools of Gal-1 were depleted by siRNA, and rGal-1 was 
added simultaneously. While a siRNA directed against Gal-1 
prevented invasion of SY5Y-TrkB cells, this effect could be 
completely rescued by addition of rGal-1 (Figure 16). This suggests a 
major importance of extracellular Gal-1 for invasion either in a 
autocrine or paracrine fashion. Similar results were obtained for the 
migratory capacity of Trk-expressing NB cells. BDNF-induced 
migration of SY5Y-TrkB cells was strongly reduced in the presence 
of a siRNA directed against Gal-1 in a scratch assay, whereas 
neurotrophin-treated SY5Y-TrkA cells or vector control cells were not 
able to migrate (Figure 18). Therefore, both the migratory and 
invasive capacity of SY5Y cells were highly dependent on the 
activation of TrkB by BDNF and these functions were strongly 
modulated by Gal-1.  
Furthermore, I analysed the consequences of interfering with BDNF 
signalling using the Trk-specific small molecule inhibitor, K252a. 
BDNF-mediated phosphorylation of Akt was used as a marker for 
TrkB activation in SY5Y-TrkB cells, in which inhibition of Akt 
sensitizes to chemotherapy (Ho et al., 2002; Jaboin et al., 2002). It has 
been previously shown that the chosen concentration of K252a (100 
nM) is sufficient to inhibit Trk phosphorylation in other model 
systems (Stephan et al., 2008). Following treatment with K252a, 
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phosphorylation of Akt was strongly reduced in BDNF-activated 
SY5Y-TrkB cells and this could not be seen in neurotrophin-treated 
SY5Y cells without TrkB expression (Figure 19). A minor increase in 
Akt phosphorylation following K252a treatment in the absence of Trk 
receptors might be attributed to its described effect on serine/threonine 
protein kinases (Tapley et al., 1992). As Gal-1 levels also decrease 
following K252a treatment, I conclude that Gal1- induction is directly 
dependent on activated TrkB in SY5Y-TrkB cells.  
In summary, I have shown that Gal-1 is correlated to the Trk receptor 
status in primary NB and that Gal-1 is a major effector of TrkB-
mediated aggressiveness. Blocking Gal-1 function clearly and 
strongly reduced the migratory and invasive capacity of TrkB-
expressing NB cells. There are already several strategies available to 
interfere with Gal-1 functions in vivo including siRNAs and small 
molecule inhibitors. These should be analysed to evaluate Gal-1 as a 
target for the treatment of NB.
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